含CCT基序的寡核苷酸对TLR7/9介导的天然免疫应答的抑制作用
|
摘要
抑制性寡核苷酸(inhibitory ODN)是一种人工合成的Toll样受体拮抗剂,具有特定核苷酸顺序的单链DNA分子,多为硫代修饰的骨架结构,长度通常在15-30核苷酸,能抑制由内源性或外源性TLR配体引起的免疫细胞的激活,在治疗与Toll受体活化的相关疾病方面展示了广阔的应用前景。
我们应用HSV-1和PR8-flu病毒建立了抑制性ODN的筛选平台,对自行设计的ODN的进行了筛选,将其中抑制活性最强的含CCT基序的ODN命名为IMO03,并对其功能特点和作用机理进行了初步的研究。实验结果表明,IMO03不仅能抑制由天然的和人工合成的TLR7/9的配体诱导的人外周血单个核细胞(PBMC)的免疫活化,也能抑制系统性红斑狼疮患者血清及其来源的DNA片段引起的人PBMC免疫激活作用,这种作用可能依赖于竞争性结合TLR受体。
IMO03不仅可以抑制人类免疫细胞的激活,还能保护小鼠避免死于CpG诱导的脓毒血症的休克。我们的研究证明了不含“G”碱基的抑制性ODN(IMO03)对脓毒血症模型小鼠具有治疗作用,而且该抑制作用有TLR选择性——只是针对TLR7/9受体的活化,并不针对TLR3/4的活化。IMO03有望开发成治疗Toll样受体相关疾病的新型免疫调节性寡核苷酸类药物。
Inhibitory oligodeoxynucleotides (ODNs), an artificial single-stranded DNA molecule typically with a 15-30 nucleotides length, could regulate innate immunity activation. Recent studies demonstrate that inhibitory ODNs show a promise to develop an agent for the treatment of diseases associated with Toll-like receptor activation.
As part of the innate immune system, TLRs recognize microbe derived molecular structures (pathogen-associated molecular patterns, PAMPs) and therefore sense the microbe invasion and consequently initiate a rapid response that is characterized by the secretion of type I interferon (IFN) and pro-inflammatory cytokines [IL-1, IL-6, tumor-necrosis factor-α(TNF-α)], depending on the nature of the microbes. In mammals, TLR1, TLR2, TLR4, TLR5, TLR6, and TLR11, expressed at the cell surface, respond to extra-cellular microbes, and TLR3, TLR7, TLR8 and TLR9, confined to intracellular compartments, respond to nucleic acids. Preferentially, TLR7 senses single-stranded RNA [ssRNA], and TLR9 senses DNA molecules including single-stranded CpG containing oligonucleotides (CpG ODN). In homeostatic conditions, TLR activation leads to a protective immune response against pathogens through multiple inflammatory pathways. On the other hand, if unwanted, TLR activation is associated with the development of a profile of diseases, designated as Toll like receptor activation associated diseases, including SLE and sepsis.
We synthesized a series of ODNs with the sequences of human MS DNA (designated as IMO-ODN) and used them to mimic human microsatellite DNA. We test whether IMO-ODNs could inhibit the activation of human PBMCs through TLR7/9-dependent. We found the screening platform by the heat-inactivated HSV-1 and PR8-flu virus as stimulus for the development of novel ODN with immunoregulatory activity. The results demonstrate that an ODN containing CCT motif, designated as IMO03, can down-regulate the immune activation of human PBMCs induced by HSV-1, flu virus,CpG ODN and imiquimod. IMO03 has been studied for its capacity of negatively regulating innate immunity induced by TLR7/TLR9 agonists in vitro and in mice.
1 Preliminary screening of inhibitory ODN
1.1 Establishment of screening platform for inhibitory ODN by inactivated virus as stimulus
Considering the virus infection causes frequently an excessively innate immune response and DNA and RNA are as nature TLR7/9 ligands. In some extent, inactivated virus can simulate the real immune response. Heat-inactivated HSV-1 and PR8-flu virus were used as stimulus respectively and the well studied inhibitory ODN, IRS954, was selected as positive inhibitory ODN. The human PBMCs were stimulated by the inactivated virus and/or IRS954, then the anti-viral activity of the culture supernatant was tested by the anti-VSV bioassay. The experimental conditions were also well optimized. The result showed that heat-inactivated HSV-1 and PR8-flu virus induced anti-VSV bioassay were inhibited by IRS954 significantly. Time point of IRS954 adding (-30~30 min) did not affect its inhibitory effect. To obtain shorten the experimental time, the supernatant were harvest after culturing PBMC with inactivated virus and ODN for 48h.
1.2 Screening of IMO-ODNs
Six IMO-ODNs were screened by“anti-VSV bioassay”. The results indicated that IMO06, IMO04 and IMO03 inhibited the anti-viral activity of the culture supernatant of human PBMCs. Their inhibition was in a dose-dependent manner. IMO01 was found almost inert. Because the inhibitory effect of IMO03 containing CCT motif was higher than IMO04 and IMO06, so IMO03 was as a more promise ODN for following experiments, and IMO01 was as a control ODN.
1.3 Inhibition of IMO03 on CpG ODN induced anti-viral activity
VSV protection assay was conducted to investigate whether IMO03 could inhibit the anti-viral activity of human PBMCs induced by CpG ODN and imiqumod. The result showed that IMO03 inhibited the anti-VSV activity induced by CpG ODN and imiquimod, but not IMO01. The results showed that the inhibitory effect of IMO03 was base on a sequence-specific manner.
1.4 Species-specificity analysis of IMO03
We replaced human PBMCs with BALB/c spleen cells and investigated whether IMO03 is still inhibitory on the activation of mouse immune cells stimulated by CpG ODN. The results showed that, in cell proliferation assay, IMO03 remarkable inhibited CpG 1826-induced proliferation of spleen cells, but not IMO01; however, in VSV protection assay, IMO03 reduced the anti-VSV activity of spleen cells induced by CpG 1585. These results indicate that there is not species-specificity for IMO03 function.
1.5 IMO03 inhibited cytokine production through TLR9 on human pDC
The effect of IMO03 on cytokine production from pDCs induced by CpG ODN was also observed. The purified pDCs were incubated with CpG 2216 or in the presence of IMO03, A151 or IMO01 for 22 h and the supernatants were collected and assayed by ELISA. When used together, IMO03 significantly inhibited IFN-αproduction from the pDCs triggered by CpG 2216. Comparatively, the inhibition displayed by IMO03 was more profound than that displayed by A151. IMO03 and IMO01 alone did not induce the IFN-α, TNF-αand IL-6 production. Obviously, IMO03, displayed a tendency to, couldn’t induce significant inhibition on the production of TNF-αand IL-6 from the pDCs treated by CpG 2216. The result indicates that IMO03 targets human pDCs, cells expressing TLR7/TLR9, to control the production of IFN-α, possibly other cytokines induced via TLR9 activation.
2. The application of IMO03 on platform of Toll-like receptor associated disease
2.1 The inhibitory effect of IMO03 on IFN production from human PBMCs stimulated with serum of SLE patients and the CpG motif-containing DNA fragment from SLE patients.
Human PBMCs were treated with or without serum from eight anti-dsDNA–positive SLE patients for 48 h in the present and absent of IMO03, and the supernatants were harvested for anti-VSV assay. Three healthy donors serum are as negative control. The results indicated that the supernatant of serum from eight anti-dsDNA–positive SLE patients incubated with PBMC protect the Vero E6 against VSV attacking,but not normal serum. IMO03 inhibited the IFN production from human PBMCs stimulated with the serum from SLE patient.
We next synthesized a CpG motif-containing fragment from a SLE patient serum, KJ-6 was complexed to Lipofectamine 2000 with human PBMCs for 48 h in the present and absent of IMO03. In anti-VSV activity bioassay, we found that KJ-6 alone also stimulates highly IFN production from human PBMCs with the help of Lipofectamine 2000. The results show that IMO03 induced a dramatic inhibition of IFN secretion. In cell proliferation assay, IMO03 remarkable inhibited KJ-6-induced proliferation of human PBMCs. Together, the data indicated that IMO03 could inhibit endogenous ligands of SLE patients by inhibiting TLR7/9 signaling.
2.2 Effect of IMO03 on cytokine-mediated lethal shock induced by TLR9 agonist in mice.
Upon the in vitro analysis, we then evaluated the in vivo effect of IMO03 in a mouse model of excessive cytokine-mediated lethal shock induced CpG ODN. To create the model, BALB/c mice were pre-sensitized with D-GalN for 1.5 h and then injected i.p. with CpG 1826. The survivals of the mice were recorded. All mice in CpG 1826 group were dead in 24 h. In contrast, 100% of mice in CpG 1826 plus IMO03 group, 40% of mice in CpG 1826 plus IMO01 group and 20% of mice in CpG 1826 plus chloroquine group were still alive in 168 h, demonstrating that IMO03 could rescue mice from excessive cytokine-mediated lethal shock induced by TLR9 activation.
3 Mechanism and characters of IMO03’s inhibition
3.1 The action of IMO03 is in a selected fashion.
To investigate whether IMO03 could also inhibit activation of other TLRs, LPS (TLR4-ligand) and Poly I:C (TLR3-ligand) were used as stimulators to induce excessive cytokine-mediated lethal shock in D-GalN-treated mice. The result showed that both Poly I:C (50μg/mouse) and LPS (1μg/mouse) could induce death of D-GalN-treated mice in 24 h. However, IMO03 couldn’t rescue D-GalN-treated mice from LPS- and Poly I:C-induced excessive cytokine-mediated lethal shock even at 250μg. This may hint that IMO03 displays the inhibitory role on innate immune response by selecting TLR9 pathway but not TLR3 and TLR4 pathways.
3.2 The action of IMO03 is in a sequence-specificity and length–dependent manner.
To analyzing the structure features of IMO03 by model mouse of cytokine-mediated lethal shock, we synthesized IMO04 containing CT motif and IMO06 containing CT motif with 20 nucleotides length. IMO06, IMO04, IMO03 are injected into sepsis model mouse in vivo separately. The result showed that IMO06 has not demonstrated any inhibitory function. But IMO04 had demonstrated certain the inhibitory function for rescuing the mice from excessive cytokine-mediated lethal shock in D-GalN-treated mice. The results indicate that the action of IMO03 is in a sequence-specificity and length -dependence manner.
3.3 Inhibitory action of IMO03 is in a time and dose-dependent manner.
We tested the suitable time for administration of IMO03 in D-GalN/CpG 1826-treated mice. IMO03 was separately injected i.p. into D-GalN sensitized mice at -1 h and -0.5 h before CpG 1826 injection, simultaneously with CpG 1826 injection or 0.5 h, 1 h and 2 h after CpG 1826 injection. The survivals of the mice were recorded. The result showed that IMO03 could effectively protect mice from CpG 1826-induced excessive cytokine-mediated lethal shock when injected at -1 h, -0.5 h or simultaneously with CpG 1826 injection but failed to display the protection role when injected in 0.5 h or later after CpG 1826 injection. This may hint that IMO03 competed with CpG 1826 at the same site on target cells.
Subsequently, dose-effect of IMO03 on resisting CpG 1826-induced lethal shock was observed in D-GalN-treated mice. All mice in groups of CpG 1826 alone or plus 6.25μg of IMO03 were dead in 24 h, whereas 30%, 50% and 80% of mice in groups of CpG 1826 plus IMO03 at 12.5μg, 25μg and other three doses of 50, 75 and 100μg were still alive in 168 h. This result reveals that 50μg of IMO03 may be an optimal dosage for rescuing mice from TLR9 activation-induced excessive cytokine-mediated lethal shock.
3.4 Inhibitory action of IMO03 isn’t due to its extracellular interaction with TLR agonists.
To observe the influence of the ways of administrating IMO03 on its inhibitory effect, inactivated flu virus PR8 or HSV-1 was premixed with IMO03 or IMO01 for 2 h at 37°C or used separately to act on human PBMCs for 48 h. The supernatants were assayed in VSV protection assays. The results show that in two different ways of administration, IMO03 inhibit IFN production induced by inactivated virus. IMO03 or IMO01, premixed or added simultaneously with inactivated flu virus PR8 or HSV-1, displayed the similar inhibition on IFN production from human PBMCs. The data indicate that IMO03 mediated inhibition isn’t due to its extracellular interaction with TLR agonists like flu virus PR8 and HSV-1.
3.5 Inhibitory action of IMO03 is possible related with target cell activation. We next tested whether IMO03 targeted pDCs to display its immune
suppression. Afterward, CpG 2216 was selected as stimulator for pDCs. The pDCs were stimulated with CpG 2216 alone or in the presence of IMO03, A151 or IMO01 for 22 h and then analyzed on a FACS Canto for its expression of surface molecules after staining with fluorescence-labeled mAbs. The result showed that the expression of CD86, CD80 and HLA-DR on the surface of pDCs was up-regulated not only by CpG 2216 (P<0.05) or A151 (P<0.05) but also by IMO03 or CpG 2216 plus IMO03. The activities of IMO03 on up-regulating the surface molecules of pDCs were similar as that of A151 but much higher than that of IMO01.⑴The results indicated that IMO03 inhibited TLR9 activation at the same time of inducing pDC’s maturation. Between the two sides does not have the contradiction.⑵Since pDCs are the major cells to produce IFN-αin response to TLR9 activation and A151, as a reported inhibitory ODN, could up-regulate the expression of CD86, CD80 and HLA-DR on the surface of pDCs, we suppose that inhibitory action of IMO03 was dependent target cell activation.
In present study, an IMO-ODN containing CCT motif, designated as IMO03, was studied for its inhibitory effect on TLR7/9 activation. It was found that IMO03 could down-regulate TLR7/9-dependent IFN-αproduction induced by viral nucleic acids in vitro, protect mice from D-GalN/CpG ODN induced lethal shock but not TLR3/4 activation-mediated death, and suppress IFN-αproduction from human pDCs induced by CpG ODN. Interestingly, IMO03 could also activate pDCs, manifested by up-regulating their MHC class II and co-stimulatory molecules. The data suggest that IMO03 could be used as a potential candidate for developing a medicament for the treatment of TLR9/TLR7 activation associated diseases by blocking the TLR7/9 signaling. Although the mechanism of inhibitory ODN is unclear, we prove that the action of an oligonucleotides containing CCT motif had been related with three primary factors including the sequence specificity, certain length and PS-modification skeleton.
我们应用HSV-1和PR8-flu病毒建立了抑制性ODN的筛选平台,对自行设计的ODN的进行了筛选,将其中抑制活性最强的含CCT基序的ODN命名为IMO03,并对其功能特点和作用机理进行了初步的研究。实验结果表明,IMO03不仅能抑制由天然的和人工合成的TLR7/9的配体诱导的人外周血单个核细胞(PBMC)的免疫活化,也能抑制系统性红斑狼疮患者血清及其来源的DNA片段引起的人PBMC免疫激活作用,这种作用可能依赖于竞争性结合TLR受体。
IMO03不仅可以抑制人类免疫细胞的激活,还能保护小鼠避免死于CpG诱导的脓毒血症的休克。我们的研究证明了不含“G”碱基的抑制性ODN(IMO03)对脓毒血症模型小鼠具有治疗作用,而且该抑制作用有TLR选择性——只是针对TLR7/9受体的活化,并不针对TLR3/4的活化。IMO03有望开发成治疗Toll样受体相关疾病的新型免疫调节性寡核苷酸类药物。
Inhibitory oligodeoxynucleotides (ODNs), an artificial single-stranded DNA molecule typically with a 15-30 nucleotides length, could regulate innate immunity activation. Recent studies demonstrate that inhibitory ODNs show a promise to develop an agent for the treatment of diseases associated with Toll-like receptor activation.
As part of the innate immune system, TLRs recognize microbe derived molecular structures (pathogen-associated molecular patterns, PAMPs) and therefore sense the microbe invasion and consequently initiate a rapid response that is characterized by the secretion of type I interferon (IFN) and pro-inflammatory cytokines [IL-1, IL-6, tumor-necrosis factor-α(TNF-α)], depending on the nature of the microbes. In mammals, TLR1, TLR2, TLR4, TLR5, TLR6, and TLR11, expressed at the cell surface, respond to extra-cellular microbes, and TLR3, TLR7, TLR8 and TLR9, confined to intracellular compartments, respond to nucleic acids. Preferentially, TLR7 senses single-stranded RNA [ssRNA], and TLR9 senses DNA molecules including single-stranded CpG containing oligonucleotides (CpG ODN). In homeostatic conditions, TLR activation leads to a protective immune response against pathogens through multiple inflammatory pathways. On the other hand, if unwanted, TLR activation is associated with the development of a profile of diseases, designated as Toll like receptor activation associated diseases, including SLE and sepsis.
We synthesized a series of ODNs with the sequences of human MS DNA (designated as IMO-ODN) and used them to mimic human microsatellite DNA. We test whether IMO-ODNs could inhibit the activation of human PBMCs through TLR7/9-dependent. We found the screening platform by the heat-inactivated HSV-1 and PR8-flu virus as stimulus for the development of novel ODN with immunoregulatory activity. The results demonstrate that an ODN containing CCT motif, designated as IMO03, can down-regulate the immune activation of human PBMCs induced by HSV-1, flu virus,CpG ODN and imiquimod. IMO03 has been studied for its capacity of negatively regulating innate immunity induced by TLR7/TLR9 agonists in vitro and in mice.
1 Preliminary screening of inhibitory ODN
1.1 Establishment of screening platform for inhibitory ODN by inactivated virus as stimulus
Considering the virus infection causes frequently an excessively innate immune response and DNA and RNA are as nature TLR7/9 ligands. In some extent, inactivated virus can simulate the real immune response. Heat-inactivated HSV-1 and PR8-flu virus were used as stimulus respectively and the well studied inhibitory ODN, IRS954, was selected as positive inhibitory ODN. The human PBMCs were stimulated by the inactivated virus and/or IRS954, then the anti-viral activity of the culture supernatant was tested by the anti-VSV bioassay. The experimental conditions were also well optimized. The result showed that heat-inactivated HSV-1 and PR8-flu virus induced anti-VSV bioassay were inhibited by IRS954 significantly. Time point of IRS954 adding (-30~30 min) did not affect its inhibitory effect. To obtain shorten the experimental time, the supernatant were harvest after culturing PBMC with inactivated virus and ODN for 48h.
1.2 Screening of IMO-ODNs
Six IMO-ODNs were screened by“anti-VSV bioassay”. The results indicated that IMO06, IMO04 and IMO03 inhibited the anti-viral activity of the culture supernatant of human PBMCs. Their inhibition was in a dose-dependent manner. IMO01 was found almost inert. Because the inhibitory effect of IMO03 containing CCT motif was higher than IMO04 and IMO06, so IMO03 was as a more promise ODN for following experiments, and IMO01 was as a control ODN.
1.3 Inhibition of IMO03 on CpG ODN induced anti-viral activity
VSV protection assay was conducted to investigate whether IMO03 could inhibit the anti-viral activity of human PBMCs induced by CpG ODN and imiqumod. The result showed that IMO03 inhibited the anti-VSV activity induced by CpG ODN and imiquimod, but not IMO01. The results showed that the inhibitory effect of IMO03 was base on a sequence-specific manner.
1.4 Species-specificity analysis of IMO03
We replaced human PBMCs with BALB/c spleen cells and investigated whether IMO03 is still inhibitory on the activation of mouse immune cells stimulated by CpG ODN. The results showed that, in cell proliferation assay, IMO03 remarkable inhibited CpG 1826-induced proliferation of spleen cells, but not IMO01; however, in VSV protection assay, IMO03 reduced the anti-VSV activity of spleen cells induced by CpG 1585. These results indicate that there is not species-specificity for IMO03 function.
1.5 IMO03 inhibited cytokine production through TLR9 on human pDC
The effect of IMO03 on cytokine production from pDCs induced by CpG ODN was also observed. The purified pDCs were incubated with CpG 2216 or in the presence of IMO03, A151 or IMO01 for 22 h and the supernatants were collected and assayed by ELISA. When used together, IMO03 significantly inhibited IFN-αproduction from the pDCs triggered by CpG 2216. Comparatively, the inhibition displayed by IMO03 was more profound than that displayed by A151. IMO03 and IMO01 alone did not induce the IFN-α, TNF-αand IL-6 production. Obviously, IMO03, displayed a tendency to, couldn’t induce significant inhibition on the production of TNF-αand IL-6 from the pDCs treated by CpG 2216. The result indicates that IMO03 targets human pDCs, cells expressing TLR7/TLR9, to control the production of IFN-α, possibly other cytokines induced via TLR9 activation.
2. The application of IMO03 on platform of Toll-like receptor associated disease
2.1 The inhibitory effect of IMO03 on IFN production from human PBMCs stimulated with serum of SLE patients and the CpG motif-containing DNA fragment from SLE patients.
Human PBMCs were treated with or without serum from eight anti-dsDNA–positive SLE patients for 48 h in the present and absent of IMO03, and the supernatants were harvested for anti-VSV assay. Three healthy donors serum are as negative control. The results indicated that the supernatant of serum from eight anti-dsDNA–positive SLE patients incubated with PBMC protect the Vero E6 against VSV attacking,but not normal serum. IMO03 inhibited the IFN production from human PBMCs stimulated with the serum from SLE patient.
We next synthesized a CpG motif-containing fragment from a SLE patient serum, KJ-6 was complexed to Lipofectamine 2000 with human PBMCs for 48 h in the present and absent of IMO03. In anti-VSV activity bioassay, we found that KJ-6 alone also stimulates highly IFN production from human PBMCs with the help of Lipofectamine 2000. The results show that IMO03 induced a dramatic inhibition of IFN secretion. In cell proliferation assay, IMO03 remarkable inhibited KJ-6-induced proliferation of human PBMCs. Together, the data indicated that IMO03 could inhibit endogenous ligands of SLE patients by inhibiting TLR7/9 signaling.
2.2 Effect of IMO03 on cytokine-mediated lethal shock induced by TLR9 agonist in mice.
Upon the in vitro analysis, we then evaluated the in vivo effect of IMO03 in a mouse model of excessive cytokine-mediated lethal shock induced CpG ODN. To create the model, BALB/c mice were pre-sensitized with D-GalN for 1.5 h and then injected i.p. with CpG 1826. The survivals of the mice were recorded. All mice in CpG 1826 group were dead in 24 h. In contrast, 100% of mice in CpG 1826 plus IMO03 group, 40% of mice in CpG 1826 plus IMO01 group and 20% of mice in CpG 1826 plus chloroquine group were still alive in 168 h, demonstrating that IMO03 could rescue mice from excessive cytokine-mediated lethal shock induced by TLR9 activation.
3 Mechanism and characters of IMO03’s inhibition
3.1 The action of IMO03 is in a selected fashion.
To investigate whether IMO03 could also inhibit activation of other TLRs, LPS (TLR4-ligand) and Poly I:C (TLR3-ligand) were used as stimulators to induce excessive cytokine-mediated lethal shock in D-GalN-treated mice. The result showed that both Poly I:C (50μg/mouse) and LPS (1μg/mouse) could induce death of D-GalN-treated mice in 24 h. However, IMO03 couldn’t rescue D-GalN-treated mice from LPS- and Poly I:C-induced excessive cytokine-mediated lethal shock even at 250μg. This may hint that IMO03 displays the inhibitory role on innate immune response by selecting TLR9 pathway but not TLR3 and TLR4 pathways.
3.2 The action of IMO03 is in a sequence-specificity and length–dependent manner.
To analyzing the structure features of IMO03 by model mouse of cytokine-mediated lethal shock, we synthesized IMO04 containing CT motif and IMO06 containing CT motif with 20 nucleotides length. IMO06, IMO04, IMO03 are injected into sepsis model mouse in vivo separately. The result showed that IMO06 has not demonstrated any inhibitory function. But IMO04 had demonstrated certain the inhibitory function for rescuing the mice from excessive cytokine-mediated lethal shock in D-GalN-treated mice. The results indicate that the action of IMO03 is in a sequence-specificity and length -dependence manner.
3.3 Inhibitory action of IMO03 is in a time and dose-dependent manner.
We tested the suitable time for administration of IMO03 in D-GalN/CpG 1826-treated mice. IMO03 was separately injected i.p. into D-GalN sensitized mice at -1 h and -0.5 h before CpG 1826 injection, simultaneously with CpG 1826 injection or 0.5 h, 1 h and 2 h after CpG 1826 injection. The survivals of the mice were recorded. The result showed that IMO03 could effectively protect mice from CpG 1826-induced excessive cytokine-mediated lethal shock when injected at -1 h, -0.5 h or simultaneously with CpG 1826 injection but failed to display the protection role when injected in 0.5 h or later after CpG 1826 injection. This may hint that IMO03 competed with CpG 1826 at the same site on target cells.
Subsequently, dose-effect of IMO03 on resisting CpG 1826-induced lethal shock was observed in D-GalN-treated mice. All mice in groups of CpG 1826 alone or plus 6.25μg of IMO03 were dead in 24 h, whereas 30%, 50% and 80% of mice in groups of CpG 1826 plus IMO03 at 12.5μg, 25μg and other three doses of 50, 75 and 100μg were still alive in 168 h. This result reveals that 50μg of IMO03 may be an optimal dosage for rescuing mice from TLR9 activation-induced excessive cytokine-mediated lethal shock.
3.4 Inhibitory action of IMO03 isn’t due to its extracellular interaction with TLR agonists.
To observe the influence of the ways of administrating IMO03 on its inhibitory effect, inactivated flu virus PR8 or HSV-1 was premixed with IMO03 or IMO01 for 2 h at 37°C or used separately to act on human PBMCs for 48 h. The supernatants were assayed in VSV protection assays. The results show that in two different ways of administration, IMO03 inhibit IFN production induced by inactivated virus. IMO03 or IMO01, premixed or added simultaneously with inactivated flu virus PR8 or HSV-1, displayed the similar inhibition on IFN production from human PBMCs. The data indicate that IMO03 mediated inhibition isn’t due to its extracellular interaction with TLR agonists like flu virus PR8 and HSV-1.
3.5 Inhibitory action of IMO03 is possible related with target cell activation. We next tested whether IMO03 targeted pDCs to display its immune
suppression. Afterward, CpG 2216 was selected as stimulator for pDCs. The pDCs were stimulated with CpG 2216 alone or in the presence of IMO03, A151 or IMO01 for 22 h and then analyzed on a FACS Canto for its expression of surface molecules after staining with fluorescence-labeled mAbs. The result showed that the expression of CD86, CD80 and HLA-DR on the surface of pDCs was up-regulated not only by CpG 2216 (P<0.05) or A151 (P<0.05) but also by IMO03 or CpG 2216 plus IMO03. The activities of IMO03 on up-regulating the surface molecules of pDCs were similar as that of A151 but much higher than that of IMO01.⑴The results indicated that IMO03 inhibited TLR9 activation at the same time of inducing pDC’s maturation. Between the two sides does not have the contradiction.⑵Since pDCs are the major cells to produce IFN-αin response to TLR9 activation and A151, as a reported inhibitory ODN, could up-regulate the expression of CD86, CD80 and HLA-DR on the surface of pDCs, we suppose that inhibitory action of IMO03 was dependent target cell activation.
In present study, an IMO-ODN containing CCT motif, designated as IMO03, was studied for its inhibitory effect on TLR7/9 activation. It was found that IMO03 could down-regulate TLR7/9-dependent IFN-αproduction induced by viral nucleic acids in vitro, protect mice from D-GalN/CpG ODN induced lethal shock but not TLR3/4 activation-mediated death, and suppress IFN-αproduction from human pDCs induced by CpG ODN. Interestingly, IMO03 could also activate pDCs, manifested by up-regulating their MHC class II and co-stimulatory molecules. The data suggest that IMO03 could be used as a potential candidate for developing a medicament for the treatment of TLR9/TLR7 activation associated diseases by blocking the TLR7/9 signaling. Although the mechanism of inhibitory ODN is unclear, we prove that the action of an oligonucleotides containing CCT motif had been related with three primary factors including the sequence specificity, certain length and PS-modification skeleton.
引文
[1]Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004 Jul; 4(7):499-511.
[2]Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006 Feb 24; 124(4):783-801.
[3]Alarcón-Segovia D, Tumlin JA, Furie RA, McKay JD, Cardiel MH, Strand V, Bagin RG, Linnik MD, Hepburn B, LJP 394 Investigator Consortium. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2003 Feb; 48(2):442-54.
[4]Alexander C, Rietschel ET. Bacterial lipopolysaccharides and innate immunity. J Endotoxin Res. 2001; 7 (3):167-202.
[5]Auf G, Chen L, Fornès P, Le Clanche C, Delattre JY, Carpentier AF. CpG-oligodeoxynucleotide rejection of a neuroblastoma in A/J mice does not induce a paraneoplastic disease. Neurosci Lett. 2002 Jul 26; 327(3):189-92.
[6]Baarsch MJ, Wannemuehler MJ, Molitor TW, Murtaugh MP. Detection of tumor necrosis factor alpha from porcine alveolar macrophages using an L929 fibroblast bioassay. J Immunol Methods. 1991 Jun 24; 140(1):15-22.
[7]Baccala R, Hoebe K, Kono DH, Beutler B, Theofilopoulos AN. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med. 2007; 13:543–51.
[8]Baenziger S, Heikenwalder M, Johansen P, Schlaepfer E, Hofer U, Miller RC, Diemand S, Honda K, Kundig TM, Aguzzi A, Speck RF. Triggering TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology. Blood. 2009; 113:377-388.
[9]Banchereau J, Pascual V, Palucka AK. Autoimmunity through cytokine-induced dendritic cell activation. Immunity. 2004 May; 20(5):539-50.
[10]Banerjee B, Kelly KJ, Fink JN, Henderson JD Jr, Bansal NK, Kurup VP. Modulation of airway inflammation by immunostimulatory CpG oligodeoxynucleotides in a murine model ofallergic aspergillosis. Infect Immun. 2004 Oct; 72(10):6087-94.
[11]Bao M, Zhang Y, Wan M, Dai L, Hu X, Wu X, Wang L, Deng P, Wang J, Chen J, Liu Y, Yu Y, Wang L. Anti-SARS-CoV immunity induced by a novel CpG oligodeoxynucleotide. Clin Immunol. 2006 Feb-Mar; 118(2-3):180-7.
[12]Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, Akira S, Chang B, Duramad O, Coffman RL. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med. 2005 Oct; 17; 202(8):1131-9.
[13]Barrat FJ, Meeker T, Chan JH, Guiducci C, Coffman RL. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol. 2007 Dec; 37(12):3582-6.
[14]Barrat FJ, Coffman RL. Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol Rev. 2008 Jun; 223:271-83.
[15]Barton GM, Kagan JC, Medzhitov R. Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nat Immunol. 2006 Jan; 7(1):49-56.
[16]B?ve U, Nordmark G, L?vgren T, R?nnelid J, Cajander S, Eloranta ML, Alm GV, R?nnblom L. Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum. 2005. 52:1185–1195.
[17]B?ve U, Alm GV, R?nnblom L. The combination of apoptotic U937 cells and lupus IgG is a potent IFN-alpha inducer. J. Immunol. 2000. 165:3519–3526.
[18]Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A,Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001 Mar 8; 344(10):699-709.
[19]Ballas ZK, Krieg AM, Warren T, Rasmussen W, Davis HL, Waldschmidt M, Weiner GJ. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol. 2001 Nov 1; 167(9):4878-86.
[20]Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science. 2001 Nov 16; 294(5546):1540–1543.
[21]Blackwell TS, Christman JW. Sepsis and cytokines: current status. Br J Anaesth. 1996 Jul; 77(1):110-7.
[22]BouléMW, Broughton C, Mackay F, Akira S, Marshak-Rothstein A, Rifkin IR. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin–immunoglobulin G complexes. J. Exp. Med. 2004; 199, 1631–1640.
[23]Buljevac D, Flach HZ, Hop WC, Hijdra D, Laman JD, Savelkoul HF, van Der MechéFG, van Doorn PA, Hintzen RQ. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 2002; 125:952-60.
[24]Buras JA, Holzmann B, Sitkovsky M. Animal models of sepsis: setting the stage. Nat Rev Drug Discov. 2005 Oct; 4(10):854-65.
[25]Calcaterra C, Sfondrini L, Rossini A, Sommariva M, Rumio C, Ménard S, Balsari A. Critical role of TLR9 in acute graft-versus-host disease. J Immunol. 2008. 181:6132-6139.
[26]Cederblad B, Blomberg S, Vallin H, Perers A, Alm GV, R?nnblom L. Patients with systemic lupus erythematosus have reduced numbers of circulating natural interferon-αproducing cells. J Autoimmun. 1998; 11:465–70.
[27]Chadha KC, Dembinski WE, Dunn CB, Aradi J, Bardos TJ, Dunn JA, Ambrus JL Sr. Effect of increasing thiolation of the polycytidylic acid strand of poly I: poly C on the alpha, beta and gamma interferon-inducing properties, antiviral and antiproliferative activities. Antiviral Res. 2004 Dec; 64(3):171-7.
[28]Chen CJ, Lin KH, Lin SC, Tsai WC, Yen JH, Chang SJ, Lu SN, Liu HW. High prevalence of immunoglobulin A antibody against Epstein-Barr virus capsid antigen in adult patients with lupus with disease flare: case control studies. J Rheumatol. 2005 Jan; 32(1):44-7.
[29]Chen Y, Lenert P, Weeratna R, McCluskie M, Wu T, Davis HL, Krieg AM. Identification of methylated CpG motifs as inhibitors of the immune stimulatory CpG motifs. Gene Ther. 2001; 8:1024-32.
[30]Chen K, Huang J, Gong W, Iribarren P, Dunlop NM, Wang JM. Toll-like receptors ininflammation, infection and cancer. Int Immunopharmacol. 2007 Oct; 7(10):1271-85.
[31]Chen M, Griffith BP, Lucia HL, Hsiung GD. Efficacy of S26308 against guinea pig cytomegalovirus infection. Antimicrob Agents Chemother. 1988 May; 32(5):678-83.
[32]Cho JY, Miller M, Baek KJ, Castaneda D, Nayar J, Roman M, Raz E, Broide DH. Immunostimulatory DNA sequences inhibit respiratory syncytial viral load, airway inflammation, and mucus secretion. J Allergy Clin Immunol. 2001 Nov; 108(5):697-702.
[33]Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, Shlomchik MJ. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity. 2006 Sep; 25(3):417-28.
[34]Coban C, Ishii KJ, Kawai T, Hemmi H, Sato S, Uematsu S, Yamamoto M, Takeuchi O,Itagaki S, Kumar N, Horii T, Akira S. Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin. J Exp Med. 2005 Jan 3; 201(1):19-25.
[35]Colonna M. Toll-like receptors and IFN-alpha: partners in autoimmunity. J Clin Invest. 2006 Sep; 116(9):2319-22.
[36]Cooper CL, Davis HL, Morris ML, Efler SM, Adhami MA, Krieg AM, Cameron DW, Heathcote J. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol. 2004 Nov; 24(6):693-701.
[37]Cornélie S, Wiel E, Lund N, Lebuffe G, Vendeville C, Riveau G, Vallet B, Ban E. Cytosine-phosphate-guanine (CpG) motifs are sensitizing agents for lipopolysaccharide in toxic shock model. Intensive Care Med. 2002 Sep; 28(9):1340-7.
[38]Critical Care Society of South Africa Working Group. Severe sepsis and the role of novel therapeutic agents. Position statement of the Critical Care Society of South Africa on severe sepsis and the role of novel therapeutic agents such as drotrecogin alfa (activated). S Afr Med J. 2003 Jun; 93(6):416-7.
[39]Cross AS, Opal SM, Sadoff JC, Gemski P. Choice of bacteria in animal models of sepsis. Infect. Immun. 1993; 61:2741–2747.
[40]Crow MK. Type I interferon in systemic lupus erythematosus. Curr Top Microbiol Immunol. 2007; 316:359-86.
[41]Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, Kalunian K, Dhar P, Vincent E, Pena-Rossi C, Wofsy D. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 2007 Dec; 56(12):4142-50.
[42]Davies DR,Rich A. The formation of a helical complex between polyinosinic acid and polycytidylic acid. Amer Chem Soc. 1958; 80:1003-1004.
[43]Deng JC, Moore TA, Newstead MW, Zeng X, Krieg AM, Standiford TJ. CpG oligodeoxynucleotides stimulate protective innate immunity against pulmonary Klebsiella infection. J Immunol. 2004 Oct 15; 173(8):5148-55.
[44]Devendra D, Eisenbarth GS. Interferon alpha--a potential link in the pathogenesis of viral-induced type 1 diabetes and autoimmunity. Clin Immunol. 2004 Jun; 111(3):225-33.
[45]Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate Antiviral Responses by Means of TLR7-Mediated Recognition of Single-Stranded RNA. Science. 2004. 303:1529-1531.
[46]Dinarello CA. Anti-cytokine therapeutics and infections. Vaccine. 2003 Jun 1; 21 Suppl 2:S24-34.
[47]Ding C. Belimumab, an anti-BLyS human monoclonal antibody for potential treatment of inflammatory autoimmune diseases. Expert Opin Biol Ther. 2008; 8: 1805-181.
[48]Donna L. Thibault, Alvina D. Chu, Kareem L. Graham, Imelda Balboni, Lowen Y. Lee, Cassidy Kohlmoos, Angela Landrigan, John P. Higgins, Robert Tibshirani, Paul J. Utz. IRF9 and STAT1 are required for IgG autoantibody production and B cell expression of TLR7 in mice. J Clin Invest. 2008 April 1; 118(4): 1417–1426.
[49]Dong L, Ito S, Ishii KJ, Klinman DM. Suppressive oligonucleotides protect against collagen-induced arthritis in mice. Arthritis Rheum. 2004 May; 50(5):1686-9.
[50]Dong L, Ito S, Ishii KJ, Klinman DM. Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB x NZW mice. Arthritis Rheum. 2005 Feb; 52(2):651-8.
[51]Fanucchi MV, Schelegle ES, Baker GL, Evans MJ, McDonald RJ, Gershwin LJ, Raz E,Hyde DM, Plopper CG, Miller LA. Immunostimulatory oligonucleotides attenuate airways remodeling in allergic monkeys. Am J Respir Crit Care Med. 2004 Dec 1; 170(11):1153-7.
[52]Field AK, Tytell AA, Lampson GP, Hilleman MR. Inducers of interferon and host resistance, II. Multistranded synthetic polynucleotide complexes. Proc. Natl. Acad. Sci. 1967; 58 1004–1010.
[53]Finberg RW, Wang JP, Kurt-Jones EA. Toll like receptors and viruses. Rev Med Virol. 2007 Jan-Feb; 17(1):35-43.
[54]Fitzgerald-Bocarsly P, Dai J, Singh S. Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history. Cytokine Growth Factor Rev. 2008 Feb; 19(1):3-19.
[55]Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RM, Benjamin E. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med. 1996 Jun 27; 334(26):1697-702.
[56]Furie R, Stohl W, Ginzler EM, Becker M, Mishra N, Chatham W, Merrill JT, Weinstein A, McCune WJ, Zhong J, Cai W, Freimuth W, Belimumab Study Group. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008; 10(5):R109.
[57]Galanos C, Freudenberg MA, Reutter W. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc. Natl. Acad. Sci. USA. 1979; 76: 5939–5943.
[58]Geeraedts F, Goutagny N, Hornung V, Severa M, de Haan A, Pool J, Wilschut J, Fitzgerald KA, Huckriede A. A Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling. PLoS Pathog. 2008; 4:e1000138.
[59]Gelman AE, Kreisel D. MyD88 is required for the Differentiation of Recipient Monocytes into Dendritic Cells and Macrophages in Orthotopic Lung Grafts. J. Immunol. 2007; Apr 178: 102.2.
[60]Glinda S. Cooper, Kathleen M. Gilbert, Eric L. Greidinger, Judith A. James, Jean C. Pfau, Leslie Reinlib, Bruce C. Richardson, Noel R. Rose Recent Advances and Opportunities in Research on Lupus: Environmental Influences and Mechanisms of Disease. Environ HealthPerspect. 2008 June; 116(6): 695–702.
[61]Gilliet M, Conrad C, Geiges M, Cozzio A, Thurlimann W, Burg G, Nestle FO, Dummer R. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol. 2004; 140:1490-1495.
[62]Gilliet M, Cao W, Liu YJ. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol. 2008 Aug; 8(8):594-606.
[63]Gilkeson GS, Conover J, Halpern M, Pisetsky DS, Feagin A, Klinman DM. Effects of bacterial DNA on cytokine production by (NZB/NZW) F1 mice. J Immunol. 1998 Oct 15; 161(8):3890-5.
[64]Gottenberg JE, Cagnard N, Lucchesi C, Letourneur F, Mistou S, Lazure T, Jacques S, Ba N, Ittah M, Lepajolec C, Labetoulle M, Ardizzone M, Sibilia J, Fournier C, Chiocchia G, Mariette X. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sj?gren's syndrome. Proc Natl Acad Sci. 2006 Feb 21; 103(8):2770-5.
[65]Goldstein DR, Tesar BM, Akira S, Lakkis FG. Critical role of the Toll-like receptor signal adaptor protein MyD88 in acute allograft rejection. J Clin Invest. 2003 May; 111(10):1571-8.
[66]G.P. Lampson, A.A. Tytell, A.K. Field, M.M. Nemes, M.R. Hilleman. Inducers of interferon and host resistance, I. Double-stranded RNA from extracts of Penicillium funiculosum. Proc. Natl. Acad. Sci. 1967; 58:782–789.
[67]Guiducci C, Ghirelli C, Marloie-Provost MA, Matray T, Coffman RL, Liu YJ, Barrat FJ, Soumelis V. PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation. J Exp Med. 2008 Feb 18; 205(2):315-22.
[68]Gursel I, Gursel M, Yamada H, Ishii KJ, Takeshita F, Klinman DM. Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation. J Immunol. 2003 Aug 1; 171(3):1393-400.
[69]Gurney KB, Colantonio AD, Blom B, Spits H, Uittenbogaart CH. Endogenous IFN-alpha production by plasmacytoid dendritic cells exerts an antiviral effect on thymic HIV-1 infection. J Immunol. 2004 Dec 15; 173(12):7269-76.
[70]H?cker H, Mischak H, Miethke T, Liptay S, Schmid R, Sparwasser T, Heeg K, Lipford GB, Wagner H. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J. 1998 Nov 2; 17(21):6230-40.
[71]Hashimoto C, Hudson KL, Anderson KV. The Toll gene of Drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein. Cell. 1988 Jan 29; 52(2):269-79.
[72]Harley JB, James JA. Epstein-Barr virus infection induces lupus autoimmunity. Bull NYU Hosp Jt Dis. 2006; 64(1-2):45-50.
[73]Haas T, Metzger J, Schmitz F, Heit A, Müller T, Latz E, Wagner H. The DNA Sugar Backbone 2 Deoxyribose Determines Toll-like Receptor 9 Activation. Immunity. 2008; 28:315-323.
[74]Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S. A Toll-like receptor recognizes bacterial DNA. Nature. 2000 Dec 7; 408(6813):740-5.
[75]Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependentsignaling pathway. Nat Immunol. 2002 Feb; 3(2):196-200.
[76]Hoshino K, Kaisho T. Nucleic acid sensing Toll-like receptors in dendritic cells. Curr Opin Immunol. 2008 Aug; 20(4):408-13.
[77]Hochrein H, Schlatter B, O'Keeffe M, Wagner C, Schmitz F, Schiemann M, Bauer S, Suter M, Wagner H. Herpes simplex virus type-1 induces IFN-alpha production via Toll-like receptor 9-dependent and -independent pathways. Proc Natl Acad Sci. 2004 Aug 3; 101(31):11416-21.
[78]Honda K, Taniguchi T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol. 2006 Sep; 6(9):644-58.
[79]Ho PP, Fontoura P, Ruiz PJ, Steinman L, Garren H. An immunomodulatory GpG oligonucleotide for the treatment of autoimmunity via the innate and adaptive immune systems. J Immunol. 2003 Nov 1; 171(9):4920-6.
[80]Hu D, Su X, Sun R, Yang G, Wang H, Ren J, Sun L, Wu X, Hu X, Yu Y, Wang L. Human microsatellite DNA mimicking oligodeoxynucleotides down-regulate TLR9-dependent and -independent activation of human immune cells. Mol Immunol. 2009 Apr; 46(7):1387-96.
[81]International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature. 2001 Feb 15; 409 (6822):860-921.
[82]Ito S, Ishii KJ, Gursel M, Shirotra H, Ihata A, Klinman DM. CpG oligodeoxynucleotides enhance neonatal resistance to Listeria infection. J Immunol. 2005 Jan 15; 174(2):777-82.
[83]James OF, Bhopal R, Howel D, Gray J, Burt AD, Metcalf JV. Primary biliary cirrhosis once rare, now common in the United Kingdom? Hepatology. 1999; 30:390-394
[84]Jahrsdorfer B, Wooldridge JE, Blackwell SE, Taylor CM, Griffith TS, Link BK, Weiner GJ. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. J Leukoc Biol. 2005 Mar; 77(3):378-87.
[85]Jaeger A, Sauder P, Kopferschmitt J, Flesch F. Clinical features and management of poisoning due to antimalarial drugs. Med Toxicol Adverse Drug Exp. 1987 Jul-Aug; 2(4):242-73.
[86]Jain VV, Businga TR, Kitagaki K, George CL, O'Shaughnessy PT, Kline JN. Mucosal immunotherapy with CpG oligodeoxynucleotides reverses a murine model of chronic asthma induced by repeated antigen exposure. Am J Physiol Lung Cell Mol Physiol. 2003 Nov; 285(5):L1137-46.
[87]Jon A. Buras, Bernhard Holzmann, Michail Sitkovsky. Animal Models of sepsis: setting the stage. Nature Reviews Drug Discovery. 2005 Oct; 4(10):854-65.
[88]Jurk M, Vollmer J. Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation. BioDrugs. 2007; 21(6):387-401.
[89]Kawai T, Akira S. Toll-like receptor downstream signaling. Arthritis Res Ther. 2005; 7(1):12-9.
[90]Kerschen EJ, Fernandez JA, Cooley BC, Yang XV, Sood R, Mosnier LO, Castellino FJ,Mackman N, Griffin JH, Weiler H. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med. 2007 Oct 1; 204(10):2439-48.
[91]Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol. 2004 Apr; 4(4):249-58.
[92]Kikuchi K, Lian ZX, Yang GX, Ansari AA, Ikehara S, Kaplan M, Miyakawa H, Coppel RL, Gershwin ME. Bacterial CpG induces hyper-IgM production in CD27 (+) memory B cells in primary biliary cirrhosis. Gastroenterology. 2005; 128:304-312.
[93]Krieg AM. CpG DNA: a pathogenic factor in systemic lupus erythematosus? J Clin Immunol. 1995 Nov; 15(6):284-92.
[94]Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995 Apr 6; 374(6522):546-9.
[95]Krieg AM. Direct immunologic activities of CpG DNA and implications for gene therapy. J Gene Med. 1999; 1:56–63.
[96]Krieg AM, Wu T, Weeratna R, Efler SM, Love-Homan L, Yang L, Yi AK, Short D, Davis HL. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci. 1998 Oct 13; 95(21):12631-6.
[97]Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 2002; 20:709-60.
[98]Krieg AM. CpG DNA: trigger of sepsis, mediator of protection, or both? Scand J Infect Dis. 2003; 35(9):653-9.
[99]Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 2006 Jun; 5(6):471-84.
[100]Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest. 2007 May; 117(5):1184-94.
[101]Krug A, Luker GD, Barchet W, Leib DA, Akira S, Colonna M. Herpes simplex virus type 1 activates murine natural interferon-producing cells through toll-like receptor 9. Blood. 2004 Feb 15; 103(4):1433-7.
[102]Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, Homey B, Cao W, Wang YH, Su B, Nestle FO, Zal T, Mellman I, Schr?der JM, Liu YJ, Gilliet M. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007 Oct 4; 449(7162):564-9.
[103]LaRosa DF, Rahman AH, Turka LA. The innate immune system in allograft rejection and tolerance. J Immunol. 2007 Jun 15; 178(12):7503-9.
[104]Lau CM, Broughton C, Tabor AS, Akira S, Flavell RA, Mamula MJ, Christensen SR, Shlomchik MJ, Viglianti GA, Rifkin IR, Marshak-Rothstein A. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med. 2005 Nov 7; 202(9):1171-7.
[105]Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature. 2002 Apr 11; 416(6881):603-7.
[106]Lenert P. Inhibitory oligodeoxynucleotides-therapeutic promise for systemic autoimmune diseases? Clin Exp Immunol. 2005 Apr; 140(1):1-10.
[107]Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol. 2005; 23:275-306.
[108]Liew FY, Xu D, Brint EK, O'Neill LA. Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol. 2005 Jun; 5(6):446-58.
[109]Lundberg P, Welander P, Han X, Cantin E. Herpes simplex virus type 1 DNA is immunostimulatory in vitro and in vivo. J Virol. 2003 Oct; 77(20):11158-69.
[110]Lünemann JD, Kamradt T, Martin R, Münz C. Epstein-barr virus: environmental trigger of multiple sclerosis? J Virol. 2007 Jul; 81(13):6777-84.
[111]Marshak-Rothstein A, Busconi L, Lau CM, Tabor AS, Leadbetter EA, Akira S, Krieg AM, Lipford GB, Viglianti GA, Rifkin IR. Comparison of CpG s-ODNs, chromatin immune complexes, and dsDNA fragment immune complexes in the TLR9-dependent activation of rheumatoid factor B cells. J Endotoxin Res. 2004; 10(4):247-51.
[112]Macfarlane DE, Manzel L. Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. J Immunol. 1998 Feb 1; 160(3):1122-31.
[113]McClain MT, Heinlen LD, Dennis GJ, Roebuck J, Harley JB, James JA. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat Med. 2005 Jan; 11(1):85-9.
[114]McKenna K, Beignon AS, Bhardwaj N. Plasmacytoid dendritic cells: linking innate and adaptive immunity. J Virol. 2005 Jan; 79(1):17-27.
[115]Means TK, Latz E, Hayashi F, Murali MR, Golenbock DT, Luster AD. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest. 2005 Feb; 115(2):407-17.
[116]Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997 Jul 24; 388(6640):394-7.
[117]Miyata M, Ito O, Kobayashi H, Sasajima T, Ohira H, Suzuki S, Kasukawa R. CpG-DNA derived from sera in systemic lupus erythematosus enhances ICAM-1 expression on endothelial cells. Ann Rheum Dis. 2001; Jul; 60(7):685-9.
[118]Michie HR, Manogue KR, Spriggs DR, Revhaug A, O'Dwyer S, Dinarello CA, Cerami A, Wolff SM, Wilmore DW. Detection of circulating tumor necrosis factor after endotoxin administration. N. Engl. J. Med. 1988; 318, 1481–1486.
[119]Moon UY, Park SJ, Oh ST, Kim WU, Park SH, Lee SH, Cho CS, Kim HY, Lee WK, Lee SK. Patients with systemic lupus erythematosus have abnormally elevated Epstein-Barr virus load in blood. Arthritis Res Ther. 2004, 6(4):R295-302.
[120]Nagaki M, Moriwaki H. Implication of cytokines: Roles of tumor necrosis factor-alpha in liver injury. Hepatol Res. 2008; (s1The 6 Japan Society of Hepatology Single Topic Conference: Liver Failure: Recent Progress and Pathogenesis to Management. 28-29 September 2007, Iwate, Japan):S19-S28.
[121]Nestle FO, Conrad C, Tun-Kyi A, Homey B, Gombert M, Boyman O, Burg G, Liu YJ,Gilliet M. Plasmacytoid predendritic cells initiate psoriasis through interferon- production. J. Exp. Med. 2005; 202: 135-143.
[122]Obermeier F, Dunger N, Strauch UG, Hofmann C, Bleich A, Grunwald N, Hedrich HJ, Aschenbrenner E, Schlegelberger B, Rogler G, Scholmerich J, Falk W. CpG motifs of bacterial DNA essentially contribute to the perpetuation of chronic intestinal inflammation. Gastroenterology. 2005; 129: 913-927.
[123]Obermeier F, Dunger N, Deml L, Herfarth H, Sch?lmerich J, Falk W. CpG motifs of bacterial DNA exacerbate colitis of dextran sulfate sodium-treated mice. Eur J Immunol. 2002;32:2084–92
[124]O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol. 2007 May; 7(5):353-64.
[125]Opal SM, Cross AS, Sadoff JC, Collins HH, Kelly NM, Victor GH, Palardy JE, Bodmer MW. Efficacy of antilipopolysaccharide and anti-tumor necrosis factor monoclonal antibodies in a neutropenic rat model of Pseudomonas sepsis. J Clin Invest. 1991 Sep; 88(3):885-90.
[126]Pastores, S. M. Drotrecogin alfa (activated): a novel therapeutic strategy for severe sepsis. Post grad Med J. 2003, 79 (927): 5-10.
[127]Pawar RD, Patole PS, Ellwart A, Lech M, Segerer S, Schlondorff D, Anders HJ. Ligands to nucleic acid-specific toll-like receptors and the onset of lupus nephritis. J Am Soc Nephrol. 2006 Dec; 17(12):3365-73.
[128]Peng WM, Yu CF, Allam JP, Oldenburg J, Bieber T, Hoch J, Eis-Hübinger AM, Novak. Inhibitory oligodeoxynucleotides downregulate herpes simplex virus-induced plasmacytoid dendritic cell type I interferon production and modulate cell function. Hum Immunol. 2007 Nov; 68(11):879-87.
[129]Peter M, Bode K, Lipford GB, Eberle F, Heeg K, Dalpke AH. Characterization of suppressive oligodeoxynucleotides that inhibit Toll-like receptor-9-mediated activation of innate immunity. Immunology. 2008 Jan; 123(1):118-28.
[130]Prinz M, Garbe F, Schmidt H, Mildner A, Gutcher I, Wolter K, Piesche M, Schroers R, Weiss E, Kirschning CJ, Rochford CD, Brück W, Becher B. Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J Clin Invest. 2006 Feb; 116(2):456-64.
[131]Pisetsky DS, Reich CF. Inhibition of murine macrophage IL-12 production by natural and synthetic DNA. Clin Immunol. 2000 Sep; 96(3):198-204.
[132]Pyles RB, Higgins D, Chalk C, Zalar A, Eiden J, Brown C, Van Nest G, Stanberry LR. Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection. J Virol. 2002 Nov; 76(22):11387-96.
[133]Richardson B, Scheibert L, Strahler J, Gross L, Hanash S, Johnson M. Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 1990; 33:1665–73.
[134]Rock FL, Hardiman G, Timans JC, Kastelein RA, Bazan JF. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci. 1998 Jan 20; 95(2):588-93.
[135]R(?)nnblom LE, Alm GV, Oberg KE. Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. J. Intern. Med. 1990.227:207–210.
[136]R(?)nnblom L, Alm GV. An etiopathogenic role for the type I IFN system in SLE. Trends Immunol. 2001 Aug; 22(8):427-31.
[137]Ronnblom L, Alm G V. The natural interferon-alpha producing cells in systemic lupus erythematosus. Hum. Immunol. 2002.63:1181–1193.
[138]R(?)nnblom L, Alm GV. Systemic lupus erythematosus and the type I interferon system. Arthritis Res Ther. 2003; 5(2):68-75.
[139]Rutz M, Metzger J, Gellert T, Luppa P, Lipford GB, Wagner H, Bauer S. Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-depen-dent manner. Eur J Immunol. 2004; 34:2541-50.
[140]Santiago-Raber, M.L., Baccala R, Haraldsson KM, Choubey D, Stewart TA, Kono DH, Theofilopoulos AN. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J. Exp. Med. 2003. 197:777–788.
[141]Sato Y, Miyata M, Sato Y, Nishimaki T, Kochi H, Kasukawa R. CpG motif-containing DNA fragments from sera of patients with systemic lupus erythematosus proliferate mononuclear cells in vitro. J. Rheumatol. 1999. 26:294–301.
[142]Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, Cinque P, Andreoni L, Trivedi P, Salvetti M, Faggioni A, Aloisi F. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med. 2007 Nov 26; 204(12):2899-912.
[143]Schoenemeyer A, Barnes BJ, Mancl ME, Latz E, Goutagny N, Pitha PM, Fitzgerald KA,Golenbock DT. The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling. J Biol Chem. 2005 Apr 29; 280(17):17005-12.
[144]Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat Immunol. 2001 Oct; 2(10):947-50.
[145]Sester DP, Naik S, Beasley SJ, Hume DA, Stacey KJ. Phosphorothioate backbonemodification modulates macrophage activation by CpG DNA. J. Immunol. 2000.165, 4165–4173.
[146]Shiau MY, Chiou HL, Lee YL, Kuo TM, Chang YH. Establishment of a consistent L929 bioassay system for TNF-alpha quantitation to evaluate the effect of lipopolysaccharide, phytomitogens and cytodifferentiation agents on cytotoxicity of TNF-alpha secreted by adherent human mononuclear cells. Mediators Inflamm. 2001.10:199-208.
[147]Shirota H, Gursel M, Klinman DM. Suppressive oligodeoxynucleotides inhibit Th1 differentiation by blocking IFN-gamma and IL-12-mediated signaling. J Immunol. 2004 Oct 15; 173(8):5002-7.
[148]Shirota H, Gursel I, Gursel M, Klinman DM. Suppressive oligodeoxynucleotides protect mice from lethal endotoxic shock. J Immunol. 2005 Apr 15; 174(8):4579-83.
[149]Simons FE, Shikishima Y, Van Nest G, Eiden JJ, HayGlass KT. Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J Allergy Clin Immunol. 2004 Jun; 113(6):1144-51.
[150]Sparwasser T, Miethke T, Lipford G, Borschert K, H?cker H, Heeg K, Wagner H. Bacterial DNA causes septic shock. Nature. 1997 386:336–337.
[151]Sparwasser T, Miethke T, Lipford G, Erdmann A, H?cker H, Heeg K, Wagner H. Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-alpha-mediated shock. Eur J Immunol. 1997 Jul; 27(7):1671-9.
[152]Stacey KJ, Young GR, Clark F, Sester DP, Roberts TL, Naik S, Sweet MJ, Hume DA. The molecular basis for the lack of immunostimulatory activity of vertebrate DNA. J Immunol. 2003; 170:3614-20.
[153]Stunz LL, Lenert P, Peckham D, Yi AK, Haxhinasto S, Chang M, Krieg AM, Ashman RF. Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells. Eur J Immunol. 2002 May; 32(5):1212-22.
[154]Sun S, Rao NL, Venable J, Thurmond R, Karlsson L. TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets. 2007 Dec; 6(4):223-35.
[155]Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol. 2005 Jan; 17(1):1-14.
[156]Tanaka Y, Yamamoto K, Takeuchi T, Nishimoto N, Miyasaka N, Sumida T, Shima Y,Takada K, Matsumoto I, Saito K, Koike T. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol. 2007; 17(3):191-7.
[157]Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, Parroche P, Drabic S, Golenbock D, Sirois C, Hua J, An LL, Audoly L, La Rosa G, Bierhaus A, Naworth P, Marshak-Rothstein A, Crow MK, Fitzgerald KA, Latz E, Kiener PA, Coyle AJ. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol. 2007 May; 8(5):487-96.
[158]Tokunaga T, Yamamoto H, Shimada S, Abe H, Fukuda T, Fujisawa Y, Furutani Y, Yano O, Kataoka T, Sudo T, et al. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J Natl Cancer Inst. 1984 Apr; 72(4):955-62.
[159]Torok HP, Glas J, Tonenchi L, Bruennler G, Folwaczny M, Folwaczny C. Crohn's disease is associated with a toll-like receptor-9 polymorphism. Gastroenterology. 2004; 127: 365-366
[160]Trieu A, Roberts TL, Dunn JA, Sweet MJ, Stacey KJ. DNA Motifs Suppressing TLR9 Responses. Crit Rev Immunol. 2006; 26(6):527-44.
[161]Us D. Cytokine storm in avian influenza. Mikrobiyol Bul. 2008; 42:365-380.
[162]Vallin, H, Blomberg, S, Alm, G.V, Cederblad, Band Ronnblom L. Patients with systemic lupus erythematosus have a circulating inducer of interferon-alpha (IFN-alpha) production acting on leucocytes resembling immature dendritic cells. Clin. Exp. Immunol. 1999. 115:196–202.
[163]Vallin H, Perers A, Alm GV, R?nnblom L. Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus. J Immunol. 1999 Dec 1; 163(11):6306-13.
[164]Viglianti GA, Lau CM, Hanley TM, Miko BA, Shlomchik MJ, Marshak-Rothstein A. Activation of autoreactive B cells by CpG dsDNA. Immunity. 2003 Dec; 19(6):837-47.
[165]Wang J, Hu Y, Deng WW, Sun B. Negative regulation of Toll-like receptor signaling pathway. Microbes Infect. 2009 Mar; 11(3):321-7.
[166]Wang JP, Bowen GN, Padden C, Cerny A, Finberg RW, Newburger PE, Kurt-Jones EA. Toll-like receptor-mediated activation of neutrophils by influenza A virus. Blood. 2008 Sep 1; 112(5):2028-34.
[167]Wang L, Jiang W, Ding G, Cao H, Lu Y, Luo P, Zhou H, Zheng J. The newly identified CpG-N ODN208 protects mice from challenge with CpG-S ODN by decreasing TNF-alpha release. Int Immunopharmacol. 2007 May; 7(5):646-55.
[168]Weighardt H, Kaiser-Moore S, Vabulas RM, Kirschning CJ, Wagner H, Holzmann B. Cutting edge: myeloid differentiation factor 88 deficiency improves resistance against sepsis caused by polymicrobial infection. J Immunol. 2002 Sep 15; 169(6):2823-7.
[169]Wilson LE, Widman D, Dikman SH, Gorevic PD. Autoimmune disease complicating antiviral therapy for hepatitis C virus infection. Semin Arthritis Rheum. 2002 Dec; 32(3):163-73.
[170]Wooldridge JE, Ballas Z, Krieg AM, Weiner GJ. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood. 1997 Apr 15; 89(8):2994-8.
[171]Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus, Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, Hayden FG, Nguyen DH, de Jong MD, Naghdaliyev A, Peiris JS, Shindo N, Soeroso S, Uyeki TM. Update on Avian Influenza A (H5N1) Virus Infection in Humans. N Engl J Med. 2008; 358: 261-273.
[172]Xagorari A, Chlichlia K. Toll-like receptors and viruses: induction of innate antiviral immune responses. Open Microbiol J. 2008; 2:49-59.
[173]Yamazaki M, Kitamura R, Kusano S, Eda H, Sato S, Okawa-Takatsuji M, Aotsuka S, Yanagi K. Elevated immunoglobulin G antibodies to the proline-rich amino-terminal region of Epstein–Barr virus nuclear antigen-2 in sera from patients with systemic connective tissue diseases and from a subgroup of Sj?gren's syndrome patients with pulmonary involvements. Clin Exp Immunol. 2005 March; 139(3): 558–568.
[174]Yee SB, Ganey PE, Roth RA. The role of Kupffer cells and TNF-alpha in monocrotaline and bacterial lipopolysaccharide-induced liver injury. Toxicol Sci. 2003 Jan; 71(1):124-32.
[175]Yi AK, Tuetken R, Redford T, Waldschmidt M, Kirsch J, Krieg AM. CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species. J Immunol. 1998 May 15; 160(10):4755-61.
[176]Yung RL, Richardson BC. Role of T cell DNA methylation in lupus syndromes. Lupus 1994; 3:487–91.
[177]Zandman-Goddard G, Shoenfeld Y. SLE and infections. Clin Rev Allergy Immunol, 2003, 25(1):29-40.
[178]Zeuner RA, Verthelyi D, Gursel M, Ishii KJ, Klinman DM. Influence of stimulatory and suppressive DNA motifs on host susceptibility to inflammatory arthritis. Arthritis Rheum. 2003 Jun; 48(6):1701-7.
[179]Zhu FG, Reich CF, Pisetsky DS. Inhibition of murine macrophage nitric oxide production by synthetic oligonucleotides. J Leukoc Biol. 2002 Apr; 71 (4):686-94.
[180]Zhu FG, Reich CF, Pisetsky DS. Inhibition of murine dendritic cell activation by synthetic phosphorothioate oligodeoxynucleotides. J Leukoc Biol. 2002 Dec; 72(6):1154-63.
[181]Zimmermann S, Egeter O, Hausmann S, Lipford GB, Rocken M, Wagner H, Heeg K. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J Immunol. 1998 Apr 15; 160 (8):3627-30.
[182]胡大利.模拟人微卫星DNA的寡核苷酸对人免疫细胞活化的抑制作用[D].吉林:吉林大学白求恩医学院,2008.
[2]Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006 Feb 24; 124(4):783-801.
[3]Alarcón-Segovia D, Tumlin JA, Furie RA, McKay JD, Cardiel MH, Strand V, Bagin RG, Linnik MD, Hepburn B, LJP 394 Investigator Consortium. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2003 Feb; 48(2):442-54.
[4]Alexander C, Rietschel ET. Bacterial lipopolysaccharides and innate immunity. J Endotoxin Res. 2001; 7 (3):167-202.
[5]Auf G, Chen L, Fornès P, Le Clanche C, Delattre JY, Carpentier AF. CpG-oligodeoxynucleotide rejection of a neuroblastoma in A/J mice does not induce a paraneoplastic disease. Neurosci Lett. 2002 Jul 26; 327(3):189-92.
[6]Baarsch MJ, Wannemuehler MJ, Molitor TW, Murtaugh MP. Detection of tumor necrosis factor alpha from porcine alveolar macrophages using an L929 fibroblast bioassay. J Immunol Methods. 1991 Jun 24; 140(1):15-22.
[7]Baccala R, Hoebe K, Kono DH, Beutler B, Theofilopoulos AN. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med. 2007; 13:543–51.
[8]Baenziger S, Heikenwalder M, Johansen P, Schlaepfer E, Hofer U, Miller RC, Diemand S, Honda K, Kundig TM, Aguzzi A, Speck RF. Triggering TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology. Blood. 2009; 113:377-388.
[9]Banchereau J, Pascual V, Palucka AK. Autoimmunity through cytokine-induced dendritic cell activation. Immunity. 2004 May; 20(5):539-50.
[10]Banerjee B, Kelly KJ, Fink JN, Henderson JD Jr, Bansal NK, Kurup VP. Modulation of airway inflammation by immunostimulatory CpG oligodeoxynucleotides in a murine model ofallergic aspergillosis. Infect Immun. 2004 Oct; 72(10):6087-94.
[11]Bao M, Zhang Y, Wan M, Dai L, Hu X, Wu X, Wang L, Deng P, Wang J, Chen J, Liu Y, Yu Y, Wang L. Anti-SARS-CoV immunity induced by a novel CpG oligodeoxynucleotide. Clin Immunol. 2006 Feb-Mar; 118(2-3):180-7.
[12]Barrat FJ, Meeker T, Gregorio J, Chan JH, Uematsu S, Akira S, Chang B, Duramad O, Coffman RL. Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J Exp Med. 2005 Oct; 17; 202(8):1131-9.
[13]Barrat FJ, Meeker T, Chan JH, Guiducci C, Coffman RL. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol. 2007 Dec; 37(12):3582-6.
[14]Barrat FJ, Coffman RL. Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol Rev. 2008 Jun; 223:271-83.
[15]Barton GM, Kagan JC, Medzhitov R. Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nat Immunol. 2006 Jan; 7(1):49-56.
[16]B?ve U, Nordmark G, L?vgren T, R?nnelid J, Cajander S, Eloranta ML, Alm GV, R?nnblom L. Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum. 2005. 52:1185–1195.
[17]B?ve U, Alm GV, R?nnblom L. The combination of apoptotic U937 cells and lupus IgG is a potent IFN-alpha inducer. J. Immunol. 2000. 165:3519–3526.
[18]Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A,Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001 Mar 8; 344(10):699-709.
[19]Ballas ZK, Krieg AM, Warren T, Rasmussen W, Davis HL, Waldschmidt M, Weiner GJ. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol. 2001 Nov 1; 167(9):4878-86.
[20]Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science. 2001 Nov 16; 294(5546):1540–1543.
[21]Blackwell TS, Christman JW. Sepsis and cytokines: current status. Br J Anaesth. 1996 Jul; 77(1):110-7.
[22]BouléMW, Broughton C, Mackay F, Akira S, Marshak-Rothstein A, Rifkin IR. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin–immunoglobulin G complexes. J. Exp. Med. 2004; 199, 1631–1640.
[23]Buljevac D, Flach HZ, Hop WC, Hijdra D, Laman JD, Savelkoul HF, van Der MechéFG, van Doorn PA, Hintzen RQ. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 2002; 125:952-60.
[24]Buras JA, Holzmann B, Sitkovsky M. Animal models of sepsis: setting the stage. Nat Rev Drug Discov. 2005 Oct; 4(10):854-65.
[25]Calcaterra C, Sfondrini L, Rossini A, Sommariva M, Rumio C, Ménard S, Balsari A. Critical role of TLR9 in acute graft-versus-host disease. J Immunol. 2008. 181:6132-6139.
[26]Cederblad B, Blomberg S, Vallin H, Perers A, Alm GV, R?nnblom L. Patients with systemic lupus erythematosus have reduced numbers of circulating natural interferon-αproducing cells. J Autoimmun. 1998; 11:465–70.
[27]Chadha KC, Dembinski WE, Dunn CB, Aradi J, Bardos TJ, Dunn JA, Ambrus JL Sr. Effect of increasing thiolation of the polycytidylic acid strand of poly I: poly C on the alpha, beta and gamma interferon-inducing properties, antiviral and antiproliferative activities. Antiviral Res. 2004 Dec; 64(3):171-7.
[28]Chen CJ, Lin KH, Lin SC, Tsai WC, Yen JH, Chang SJ, Lu SN, Liu HW. High prevalence of immunoglobulin A antibody against Epstein-Barr virus capsid antigen in adult patients with lupus with disease flare: case control studies. J Rheumatol. 2005 Jan; 32(1):44-7.
[29]Chen Y, Lenert P, Weeratna R, McCluskie M, Wu T, Davis HL, Krieg AM. Identification of methylated CpG motifs as inhibitors of the immune stimulatory CpG motifs. Gene Ther. 2001; 8:1024-32.
[30]Chen K, Huang J, Gong W, Iribarren P, Dunlop NM, Wang JM. Toll-like receptors ininflammation, infection and cancer. Int Immunopharmacol. 2007 Oct; 7(10):1271-85.
[31]Chen M, Griffith BP, Lucia HL, Hsiung GD. Efficacy of S26308 against guinea pig cytomegalovirus infection. Antimicrob Agents Chemother. 1988 May; 32(5):678-83.
[32]Cho JY, Miller M, Baek KJ, Castaneda D, Nayar J, Roman M, Raz E, Broide DH. Immunostimulatory DNA sequences inhibit respiratory syncytial viral load, airway inflammation, and mucus secretion. J Allergy Clin Immunol. 2001 Nov; 108(5):697-702.
[33]Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, Shlomchik MJ. Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing inflammatory and regulatory roles in a murine model of lupus. Immunity. 2006 Sep; 25(3):417-28.
[34]Coban C, Ishii KJ, Kawai T, Hemmi H, Sato S, Uematsu S, Yamamoto M, Takeuchi O,Itagaki S, Kumar N, Horii T, Akira S. Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin. J Exp Med. 2005 Jan 3; 201(1):19-25.
[35]Colonna M. Toll-like receptors and IFN-alpha: partners in autoimmunity. J Clin Invest. 2006 Sep; 116(9):2319-22.
[36]Cooper CL, Davis HL, Morris ML, Efler SM, Adhami MA, Krieg AM, Cameron DW, Heathcote J. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol. 2004 Nov; 24(6):693-701.
[37]Cornélie S, Wiel E, Lund N, Lebuffe G, Vendeville C, Riveau G, Vallet B, Ban E. Cytosine-phosphate-guanine (CpG) motifs are sensitizing agents for lipopolysaccharide in toxic shock model. Intensive Care Med. 2002 Sep; 28(9):1340-7.
[38]Critical Care Society of South Africa Working Group. Severe sepsis and the role of novel therapeutic agents. Position statement of the Critical Care Society of South Africa on severe sepsis and the role of novel therapeutic agents such as drotrecogin alfa (activated). S Afr Med J. 2003 Jun; 93(6):416-7.
[39]Cross AS, Opal SM, Sadoff JC, Gemski P. Choice of bacteria in animal models of sepsis. Infect. Immun. 1993; 61:2741–2747.
[40]Crow MK. Type I interferon in systemic lupus erythematosus. Curr Top Microbiol Immunol. 2007; 316:359-86.
[41]Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, Kalunian K, Dhar P, Vincent E, Pena-Rossi C, Wofsy D. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 2007 Dec; 56(12):4142-50.
[42]Davies DR,Rich A. The formation of a helical complex between polyinosinic acid and polycytidylic acid. Amer Chem Soc. 1958; 80:1003-1004.
[43]Deng JC, Moore TA, Newstead MW, Zeng X, Krieg AM, Standiford TJ. CpG oligodeoxynucleotides stimulate protective innate immunity against pulmonary Klebsiella infection. J Immunol. 2004 Oct 15; 173(8):5148-55.
[44]Devendra D, Eisenbarth GS. Interferon alpha--a potential link in the pathogenesis of viral-induced type 1 diabetes and autoimmunity. Clin Immunol. 2004 Jun; 111(3):225-33.
[45]Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate Antiviral Responses by Means of TLR7-Mediated Recognition of Single-Stranded RNA. Science. 2004. 303:1529-1531.
[46]Dinarello CA. Anti-cytokine therapeutics and infections. Vaccine. 2003 Jun 1; 21 Suppl 2:S24-34.
[47]Ding C. Belimumab, an anti-BLyS human monoclonal antibody for potential treatment of inflammatory autoimmune diseases. Expert Opin Biol Ther. 2008; 8: 1805-181.
[48]Donna L. Thibault, Alvina D. Chu, Kareem L. Graham, Imelda Balboni, Lowen Y. Lee, Cassidy Kohlmoos, Angela Landrigan, John P. Higgins, Robert Tibshirani, Paul J. Utz. IRF9 and STAT1 are required for IgG autoantibody production and B cell expression of TLR7 in mice. J Clin Invest. 2008 April 1; 118(4): 1417–1426.
[49]Dong L, Ito S, Ishii KJ, Klinman DM. Suppressive oligonucleotides protect against collagen-induced arthritis in mice. Arthritis Rheum. 2004 May; 50(5):1686-9.
[50]Dong L, Ito S, Ishii KJ, Klinman DM. Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB x NZW mice. Arthritis Rheum. 2005 Feb; 52(2):651-8.
[51]Fanucchi MV, Schelegle ES, Baker GL, Evans MJ, McDonald RJ, Gershwin LJ, Raz E,Hyde DM, Plopper CG, Miller LA. Immunostimulatory oligonucleotides attenuate airways remodeling in allergic monkeys. Am J Respir Crit Care Med. 2004 Dec 1; 170(11):1153-7.
[52]Field AK, Tytell AA, Lampson GP, Hilleman MR. Inducers of interferon and host resistance, II. Multistranded synthetic polynucleotide complexes. Proc. Natl. Acad. Sci. 1967; 58 1004–1010.
[53]Finberg RW, Wang JP, Kurt-Jones EA. Toll like receptors and viruses. Rev Med Virol. 2007 Jan-Feb; 17(1):35-43.
[54]Fitzgerald-Bocarsly P, Dai J, Singh S. Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history. Cytokine Growth Factor Rev. 2008 Feb; 19(1):3-19.
[55]Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, Abraham E, Schein RM, Benjamin E. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med. 1996 Jun 27; 334(26):1697-702.
[56]Furie R, Stohl W, Ginzler EM, Becker M, Mishra N, Chatham W, Merrill JT, Weinstein A, McCune WJ, Zhong J, Cai W, Freimuth W, Belimumab Study Group. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008; 10(5):R109.
[57]Galanos C, Freudenberg MA, Reutter W. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc. Natl. Acad. Sci. USA. 1979; 76: 5939–5943.
[58]Geeraedts F, Goutagny N, Hornung V, Severa M, de Haan A, Pool J, Wilschut J, Fitzgerald KA, Huckriede A. A Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling. PLoS Pathog. 2008; 4:e1000138.
[59]Gelman AE, Kreisel D. MyD88 is required for the Differentiation of Recipient Monocytes into Dendritic Cells and Macrophages in Orthotopic Lung Grafts. J. Immunol. 2007; Apr 178: 102.2.
[60]Glinda S. Cooper, Kathleen M. Gilbert, Eric L. Greidinger, Judith A. James, Jean C. Pfau, Leslie Reinlib, Bruce C. Richardson, Noel R. Rose Recent Advances and Opportunities in Research on Lupus: Environmental Influences and Mechanisms of Disease. Environ HealthPerspect. 2008 June; 116(6): 695–702.
[61]Gilliet M, Conrad C, Geiges M, Cozzio A, Thurlimann W, Burg G, Nestle FO, Dummer R. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol. 2004; 140:1490-1495.
[62]Gilliet M, Cao W, Liu YJ. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol. 2008 Aug; 8(8):594-606.
[63]Gilkeson GS, Conover J, Halpern M, Pisetsky DS, Feagin A, Klinman DM. Effects of bacterial DNA on cytokine production by (NZB/NZW) F1 mice. J Immunol. 1998 Oct 15; 161(8):3890-5.
[64]Gottenberg JE, Cagnard N, Lucchesi C, Letourneur F, Mistou S, Lazure T, Jacques S, Ba N, Ittah M, Lepajolec C, Labetoulle M, Ardizzone M, Sibilia J, Fournier C, Chiocchia G, Mariette X. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sj?gren's syndrome. Proc Natl Acad Sci. 2006 Feb 21; 103(8):2770-5.
[65]Goldstein DR, Tesar BM, Akira S, Lakkis FG. Critical role of the Toll-like receptor signal adaptor protein MyD88 in acute allograft rejection. J Clin Invest. 2003 May; 111(10):1571-8.
[66]G.P. Lampson, A.A. Tytell, A.K. Field, M.M. Nemes, M.R. Hilleman. Inducers of interferon and host resistance, I. Double-stranded RNA from extracts of Penicillium funiculosum. Proc. Natl. Acad. Sci. 1967; 58:782–789.
[67]Guiducci C, Ghirelli C, Marloie-Provost MA, Matray T, Coffman RL, Liu YJ, Barrat FJ, Soumelis V. PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid predendritic cells in response to TLR activation. J Exp Med. 2008 Feb 18; 205(2):315-22.
[68]Gursel I, Gursel M, Yamada H, Ishii KJ, Takeshita F, Klinman DM. Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation. J Immunol. 2003 Aug 1; 171(3):1393-400.
[69]Gurney KB, Colantonio AD, Blom B, Spits H, Uittenbogaart CH. Endogenous IFN-alpha production by plasmacytoid dendritic cells exerts an antiviral effect on thymic HIV-1 infection. J Immunol. 2004 Dec 15; 173(12):7269-76.
[70]H?cker H, Mischak H, Miethke T, Liptay S, Schmid R, Sparwasser T, Heeg K, Lipford GB, Wagner H. CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J. 1998 Nov 2; 17(21):6230-40.
[71]Hashimoto C, Hudson KL, Anderson KV. The Toll gene of Drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein. Cell. 1988 Jan 29; 52(2):269-79.
[72]Harley JB, James JA. Epstein-Barr virus infection induces lupus autoimmunity. Bull NYU Hosp Jt Dis. 2006; 64(1-2):45-50.
[73]Haas T, Metzger J, Schmitz F, Heit A, Müller T, Latz E, Wagner H. The DNA Sugar Backbone 2 Deoxyribose Determines Toll-like Receptor 9 Activation. Immunity. 2008; 28:315-323.
[74]Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S. A Toll-like receptor recognizes bacterial DNA. Nature. 2000 Dec 7; 408(6813):740-5.
[75]Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependentsignaling pathway. Nat Immunol. 2002 Feb; 3(2):196-200.
[76]Hoshino K, Kaisho T. Nucleic acid sensing Toll-like receptors in dendritic cells. Curr Opin Immunol. 2008 Aug; 20(4):408-13.
[77]Hochrein H, Schlatter B, O'Keeffe M, Wagner C, Schmitz F, Schiemann M, Bauer S, Suter M, Wagner H. Herpes simplex virus type-1 induces IFN-alpha production via Toll-like receptor 9-dependent and -independent pathways. Proc Natl Acad Sci. 2004 Aug 3; 101(31):11416-21.
[78]Honda K, Taniguchi T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol. 2006 Sep; 6(9):644-58.
[79]Ho PP, Fontoura P, Ruiz PJ, Steinman L, Garren H. An immunomodulatory GpG oligonucleotide for the treatment of autoimmunity via the innate and adaptive immune systems. J Immunol. 2003 Nov 1; 171(9):4920-6.
[80]Hu D, Su X, Sun R, Yang G, Wang H, Ren J, Sun L, Wu X, Hu X, Yu Y, Wang L. Human microsatellite DNA mimicking oligodeoxynucleotides down-regulate TLR9-dependent and -independent activation of human immune cells. Mol Immunol. 2009 Apr; 46(7):1387-96.
[81]International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature. 2001 Feb 15; 409 (6822):860-921.
[82]Ito S, Ishii KJ, Gursel M, Shirotra H, Ihata A, Klinman DM. CpG oligodeoxynucleotides enhance neonatal resistance to Listeria infection. J Immunol. 2005 Jan 15; 174(2):777-82.
[83]James OF, Bhopal R, Howel D, Gray J, Burt AD, Metcalf JV. Primary biliary cirrhosis once rare, now common in the United Kingdom? Hepatology. 1999; 30:390-394
[84]Jahrsdorfer B, Wooldridge JE, Blackwell SE, Taylor CM, Griffith TS, Link BK, Weiner GJ. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. J Leukoc Biol. 2005 Mar; 77(3):378-87.
[85]Jaeger A, Sauder P, Kopferschmitt J, Flesch F. Clinical features and management of poisoning due to antimalarial drugs. Med Toxicol Adverse Drug Exp. 1987 Jul-Aug; 2(4):242-73.
[86]Jain VV, Businga TR, Kitagaki K, George CL, O'Shaughnessy PT, Kline JN. Mucosal immunotherapy with CpG oligodeoxynucleotides reverses a murine model of chronic asthma induced by repeated antigen exposure. Am J Physiol Lung Cell Mol Physiol. 2003 Nov; 285(5):L1137-46.
[87]Jon A. Buras, Bernhard Holzmann, Michail Sitkovsky. Animal Models of sepsis: setting the stage. Nature Reviews Drug Discovery. 2005 Oct; 4(10):854-65.
[88]Jurk M, Vollmer J. Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation. BioDrugs. 2007; 21(6):387-401.
[89]Kawai T, Akira S. Toll-like receptor downstream signaling. Arthritis Res Ther. 2005; 7(1):12-9.
[90]Kerschen EJ, Fernandez JA, Cooley BC, Yang XV, Sood R, Mosnier LO, Castellino FJ,Mackman N, Griffin JH, Weiler H. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med. 2007 Oct 1; 204(10):2439-48.
[91]Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol. 2004 Apr; 4(4):249-58.
[92]Kikuchi K, Lian ZX, Yang GX, Ansari AA, Ikehara S, Kaplan M, Miyakawa H, Coppel RL, Gershwin ME. Bacterial CpG induces hyper-IgM production in CD27 (+) memory B cells in primary biliary cirrhosis. Gastroenterology. 2005; 128:304-312.
[93]Krieg AM. CpG DNA: a pathogenic factor in systemic lupus erythematosus? J Clin Immunol. 1995 Nov; 15(6):284-92.
[94]Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995 Apr 6; 374(6522):546-9.
[95]Krieg AM. Direct immunologic activities of CpG DNA and implications for gene therapy. J Gene Med. 1999; 1:56–63.
[96]Krieg AM, Wu T, Weeratna R, Efler SM, Love-Homan L, Yang L, Yi AK, Short D, Davis HL. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci. 1998 Oct 13; 95(21):12631-6.
[97]Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 2002; 20:709-60.
[98]Krieg AM. CpG DNA: trigger of sepsis, mediator of protection, or both? Scand J Infect Dis. 2003; 35(9):653-9.
[99]Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 2006 Jun; 5(6):471-84.
[100]Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest. 2007 May; 117(5):1184-94.
[101]Krug A, Luker GD, Barchet W, Leib DA, Akira S, Colonna M. Herpes simplex virus type 1 activates murine natural interferon-producing cells through toll-like receptor 9. Blood. 2004 Feb 15; 103(4):1433-7.
[102]Lande R, Gregorio J, Facchinetti V, Chatterjee B, Wang YH, Homey B, Cao W, Wang YH, Su B, Nestle FO, Zal T, Mellman I, Schr?der JM, Liu YJ, Gilliet M. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 2007 Oct 4; 449(7162):564-9.
[103]LaRosa DF, Rahman AH, Turka LA. The innate immune system in allograft rejection and tolerance. J Immunol. 2007 Jun 15; 178(12):7503-9.
[104]Lau CM, Broughton C, Tabor AS, Akira S, Flavell RA, Mamula MJ, Christensen SR, Shlomchik MJ, Viglianti GA, Rifkin IR, Marshak-Rothstein A. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med. 2005 Nov 7; 202(9):1171-7.
[105]Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature. 2002 Apr 11; 416(6881):603-7.
[106]Lenert P. Inhibitory oligodeoxynucleotides-therapeutic promise for systemic autoimmune diseases? Clin Exp Immunol. 2005 Apr; 140(1):1-10.
[107]Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol. 2005; 23:275-306.
[108]Liew FY, Xu D, Brint EK, O'Neill LA. Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol. 2005 Jun; 5(6):446-58.
[109]Lundberg P, Welander P, Han X, Cantin E. Herpes simplex virus type 1 DNA is immunostimulatory in vitro and in vivo. J Virol. 2003 Oct; 77(20):11158-69.
[110]Lünemann JD, Kamradt T, Martin R, Münz C. Epstein-barr virus: environmental trigger of multiple sclerosis? J Virol. 2007 Jul; 81(13):6777-84.
[111]Marshak-Rothstein A, Busconi L, Lau CM, Tabor AS, Leadbetter EA, Akira S, Krieg AM, Lipford GB, Viglianti GA, Rifkin IR. Comparison of CpG s-ODNs, chromatin immune complexes, and dsDNA fragment immune complexes in the TLR9-dependent activation of rheumatoid factor B cells. J Endotoxin Res. 2004; 10(4):247-51.
[112]Macfarlane DE, Manzel L. Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. J Immunol. 1998 Feb 1; 160(3):1122-31.
[113]McClain MT, Heinlen LD, Dennis GJ, Roebuck J, Harley JB, James JA. Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat Med. 2005 Jan; 11(1):85-9.
[114]McKenna K, Beignon AS, Bhardwaj N. Plasmacytoid dendritic cells: linking innate and adaptive immunity. J Virol. 2005 Jan; 79(1):17-27.
[115]Means TK, Latz E, Hayashi F, Murali MR, Golenbock DT, Luster AD. Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest. 2005 Feb; 115(2):407-17.
[116]Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997 Jul 24; 388(6640):394-7.
[117]Miyata M, Ito O, Kobayashi H, Sasajima T, Ohira H, Suzuki S, Kasukawa R. CpG-DNA derived from sera in systemic lupus erythematosus enhances ICAM-1 expression on endothelial cells. Ann Rheum Dis. 2001; Jul; 60(7):685-9.
[118]Michie HR, Manogue KR, Spriggs DR, Revhaug A, O'Dwyer S, Dinarello CA, Cerami A, Wolff SM, Wilmore DW. Detection of circulating tumor necrosis factor after endotoxin administration. N. Engl. J. Med. 1988; 318, 1481–1486.
[119]Moon UY, Park SJ, Oh ST, Kim WU, Park SH, Lee SH, Cho CS, Kim HY, Lee WK, Lee SK. Patients with systemic lupus erythematosus have abnormally elevated Epstein-Barr virus load in blood. Arthritis Res Ther. 2004, 6(4):R295-302.
[120]Nagaki M, Moriwaki H. Implication of cytokines: Roles of tumor necrosis factor-alpha in liver injury. Hepatol Res. 2008; (s1The 6 Japan Society of Hepatology Single Topic Conference: Liver Failure: Recent Progress and Pathogenesis to Management. 28-29 September 2007, Iwate, Japan):S19-S28.
[121]Nestle FO, Conrad C, Tun-Kyi A, Homey B, Gombert M, Boyman O, Burg G, Liu YJ,Gilliet M. Plasmacytoid predendritic cells initiate psoriasis through interferon- production. J. Exp. Med. 2005; 202: 135-143.
[122]Obermeier F, Dunger N, Strauch UG, Hofmann C, Bleich A, Grunwald N, Hedrich HJ, Aschenbrenner E, Schlegelberger B, Rogler G, Scholmerich J, Falk W. CpG motifs of bacterial DNA essentially contribute to the perpetuation of chronic intestinal inflammation. Gastroenterology. 2005; 129: 913-927.
[123]Obermeier F, Dunger N, Deml L, Herfarth H, Sch?lmerich J, Falk W. CpG motifs of bacterial DNA exacerbate colitis of dextran sulfate sodium-treated mice. Eur J Immunol. 2002;32:2084–92
[124]O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol. 2007 May; 7(5):353-64.
[125]Opal SM, Cross AS, Sadoff JC, Collins HH, Kelly NM, Victor GH, Palardy JE, Bodmer MW. Efficacy of antilipopolysaccharide and anti-tumor necrosis factor monoclonal antibodies in a neutropenic rat model of Pseudomonas sepsis. J Clin Invest. 1991 Sep; 88(3):885-90.
[126]Pastores, S. M. Drotrecogin alfa (activated): a novel therapeutic strategy for severe sepsis. Post grad Med J. 2003, 79 (927): 5-10.
[127]Pawar RD, Patole PS, Ellwart A, Lech M, Segerer S, Schlondorff D, Anders HJ. Ligands to nucleic acid-specific toll-like receptors and the onset of lupus nephritis. J Am Soc Nephrol. 2006 Dec; 17(12):3365-73.
[128]Peng WM, Yu CF, Allam JP, Oldenburg J, Bieber T, Hoch J, Eis-Hübinger AM, Novak. Inhibitory oligodeoxynucleotides downregulate herpes simplex virus-induced plasmacytoid dendritic cell type I interferon production and modulate cell function. Hum Immunol. 2007 Nov; 68(11):879-87.
[129]Peter M, Bode K, Lipford GB, Eberle F, Heeg K, Dalpke AH. Characterization of suppressive oligodeoxynucleotides that inhibit Toll-like receptor-9-mediated activation of innate immunity. Immunology. 2008 Jan; 123(1):118-28.
[130]Prinz M, Garbe F, Schmidt H, Mildner A, Gutcher I, Wolter K, Piesche M, Schroers R, Weiss E, Kirschning CJ, Rochford CD, Brück W, Becher B. Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J Clin Invest. 2006 Feb; 116(2):456-64.
[131]Pisetsky DS, Reich CF. Inhibition of murine macrophage IL-12 production by natural and synthetic DNA. Clin Immunol. 2000 Sep; 96(3):198-204.
[132]Pyles RB, Higgins D, Chalk C, Zalar A, Eiden J, Brown C, Van Nest G, Stanberry LR. Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection. J Virol. 2002 Nov; 76(22):11387-96.
[133]Richardson B, Scheibert L, Strahler J, Gross L, Hanash S, Johnson M. Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 1990; 33:1665–73.
[134]Rock FL, Hardiman G, Timans JC, Kastelein RA, Bazan JF. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci. 1998 Jan 20; 95(2):588-93.
[135]R(?)nnblom LE, Alm GV, Oberg KE. Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. J. Intern. Med. 1990.227:207–210.
[136]R(?)nnblom L, Alm GV. An etiopathogenic role for the type I IFN system in SLE. Trends Immunol. 2001 Aug; 22(8):427-31.
[137]Ronnblom L, Alm G V. The natural interferon-alpha producing cells in systemic lupus erythematosus. Hum. Immunol. 2002.63:1181–1193.
[138]R(?)nnblom L, Alm GV. Systemic lupus erythematosus and the type I interferon system. Arthritis Res Ther. 2003; 5(2):68-75.
[139]Rutz M, Metzger J, Gellert T, Luppa P, Lipford GB, Wagner H, Bauer S. Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-depen-dent manner. Eur J Immunol. 2004; 34:2541-50.
[140]Santiago-Raber, M.L., Baccala R, Haraldsson KM, Choubey D, Stewart TA, Kono DH, Theofilopoulos AN. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J. Exp. Med. 2003. 197:777–788.
[141]Sato Y, Miyata M, Sato Y, Nishimaki T, Kochi H, Kasukawa R. CpG motif-containing DNA fragments from sera of patients with systemic lupus erythematosus proliferate mononuclear cells in vitro. J. Rheumatol. 1999. 26:294–301.
[142]Serafini B, Rosicarelli B, Franciotta D, Magliozzi R, Reynolds R, Cinque P, Andreoni L, Trivedi P, Salvetti M, Faggioni A, Aloisi F. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med. 2007 Nov 26; 204(12):2899-912.
[143]Schoenemeyer A, Barnes BJ, Mancl ME, Latz E, Goutagny N, Pitha PM, Fitzgerald KA,Golenbock DT. The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling. J Biol Chem. 2005 Apr 29; 280(17):17005-12.
[144]Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat Immunol. 2001 Oct; 2(10):947-50.
[145]Sester DP, Naik S, Beasley SJ, Hume DA, Stacey KJ. Phosphorothioate backbonemodification modulates macrophage activation by CpG DNA. J. Immunol. 2000.165, 4165–4173.
[146]Shiau MY, Chiou HL, Lee YL, Kuo TM, Chang YH. Establishment of a consistent L929 bioassay system for TNF-alpha quantitation to evaluate the effect of lipopolysaccharide, phytomitogens and cytodifferentiation agents on cytotoxicity of TNF-alpha secreted by adherent human mononuclear cells. Mediators Inflamm. 2001.10:199-208.
[147]Shirota H, Gursel M, Klinman DM. Suppressive oligodeoxynucleotides inhibit Th1 differentiation by blocking IFN-gamma and IL-12-mediated signaling. J Immunol. 2004 Oct 15; 173(8):5002-7.
[148]Shirota H, Gursel I, Gursel M, Klinman DM. Suppressive oligodeoxynucleotides protect mice from lethal endotoxic shock. J Immunol. 2005 Apr 15; 174(8):4579-83.
[149]Simons FE, Shikishima Y, Van Nest G, Eiden JJ, HayGlass KT. Selective immune redirection in humans with ragweed allergy by injecting Amb a 1 linked to immunostimulatory DNA. J Allergy Clin Immunol. 2004 Jun; 113(6):1144-51.
[150]Sparwasser T, Miethke T, Lipford G, Borschert K, H?cker H, Heeg K, Wagner H. Bacterial DNA causes septic shock. Nature. 1997 386:336–337.
[151]Sparwasser T, Miethke T, Lipford G, Erdmann A, H?cker H, Heeg K, Wagner H. Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-alpha-mediated shock. Eur J Immunol. 1997 Jul; 27(7):1671-9.
[152]Stacey KJ, Young GR, Clark F, Sester DP, Roberts TL, Naik S, Sweet MJ, Hume DA. The molecular basis for the lack of immunostimulatory activity of vertebrate DNA. J Immunol. 2003; 170:3614-20.
[153]Stunz LL, Lenert P, Peckham D, Yi AK, Haxhinasto S, Chang M, Krieg AM, Ashman RF. Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells. Eur J Immunol. 2002 May; 32(5):1212-22.
[154]Sun S, Rao NL, Venable J, Thurmond R, Karlsson L. TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm Allergy Drug Targets. 2007 Dec; 6(4):223-35.
[155]Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol. 2005 Jan; 17(1):1-14.
[156]Tanaka Y, Yamamoto K, Takeuchi T, Nishimoto N, Miyasaka N, Sumida T, Shima Y,Takada K, Matsumoto I, Saito K, Koike T. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol. 2007; 17(3):191-7.
[157]Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, Parroche P, Drabic S, Golenbock D, Sirois C, Hua J, An LL, Audoly L, La Rosa G, Bierhaus A, Naworth P, Marshak-Rothstein A, Crow MK, Fitzgerald KA, Latz E, Kiener PA, Coyle AJ. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol. 2007 May; 8(5):487-96.
[158]Tokunaga T, Yamamoto H, Shimada S, Abe H, Fukuda T, Fujisawa Y, Furutani Y, Yano O, Kataoka T, Sudo T, et al. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J Natl Cancer Inst. 1984 Apr; 72(4):955-62.
[159]Torok HP, Glas J, Tonenchi L, Bruennler G, Folwaczny M, Folwaczny C. Crohn's disease is associated with a toll-like receptor-9 polymorphism. Gastroenterology. 2004; 127: 365-366
[160]Trieu A, Roberts TL, Dunn JA, Sweet MJ, Stacey KJ. DNA Motifs Suppressing TLR9 Responses. Crit Rev Immunol. 2006; 26(6):527-44.
[161]Us D. Cytokine storm in avian influenza. Mikrobiyol Bul. 2008; 42:365-380.
[162]Vallin, H, Blomberg, S, Alm, G.V, Cederblad, Band Ronnblom L. Patients with systemic lupus erythematosus have a circulating inducer of interferon-alpha (IFN-alpha) production acting on leucocytes resembling immature dendritic cells. Clin. Exp. Immunol. 1999. 115:196–202.
[163]Vallin H, Perers A, Alm GV, R?nnblom L. Anti-double-stranded DNA antibodies and immunostimulatory plasmid DNA in combination mimic the endogenous IFN-alpha inducer in systemic lupus erythematosus. J Immunol. 1999 Dec 1; 163(11):6306-13.
[164]Viglianti GA, Lau CM, Hanley TM, Miko BA, Shlomchik MJ, Marshak-Rothstein A. Activation of autoreactive B cells by CpG dsDNA. Immunity. 2003 Dec; 19(6):837-47.
[165]Wang J, Hu Y, Deng WW, Sun B. Negative regulation of Toll-like receptor signaling pathway. Microbes Infect. 2009 Mar; 11(3):321-7.
[166]Wang JP, Bowen GN, Padden C, Cerny A, Finberg RW, Newburger PE, Kurt-Jones EA. Toll-like receptor-mediated activation of neutrophils by influenza A virus. Blood. 2008 Sep 1; 112(5):2028-34.
[167]Wang L, Jiang W, Ding G, Cao H, Lu Y, Luo P, Zhou H, Zheng J. The newly identified CpG-N ODN208 protects mice from challenge with CpG-S ODN by decreasing TNF-alpha release. Int Immunopharmacol. 2007 May; 7(5):646-55.
[168]Weighardt H, Kaiser-Moore S, Vabulas RM, Kirschning CJ, Wagner H, Holzmann B. Cutting edge: myeloid differentiation factor 88 deficiency improves resistance against sepsis caused by polymicrobial infection. J Immunol. 2002 Sep 15; 169(6):2823-7.
[169]Wilson LE, Widman D, Dikman SH, Gorevic PD. Autoimmune disease complicating antiviral therapy for hepatitis C virus infection. Semin Arthritis Rheum. 2002 Dec; 32(3):163-73.
[170]Wooldridge JE, Ballas Z, Krieg AM, Weiner GJ. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood. 1997 Apr 15; 89(8):2994-8.
[171]Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus, Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, Hayden FG, Nguyen DH, de Jong MD, Naghdaliyev A, Peiris JS, Shindo N, Soeroso S, Uyeki TM. Update on Avian Influenza A (H5N1) Virus Infection in Humans. N Engl J Med. 2008; 358: 261-273.
[172]Xagorari A, Chlichlia K. Toll-like receptors and viruses: induction of innate antiviral immune responses. Open Microbiol J. 2008; 2:49-59.
[173]Yamazaki M, Kitamura R, Kusano S, Eda H, Sato S, Okawa-Takatsuji M, Aotsuka S, Yanagi K. Elevated immunoglobulin G antibodies to the proline-rich amino-terminal region of Epstein–Barr virus nuclear antigen-2 in sera from patients with systemic connective tissue diseases and from a subgroup of Sj?gren's syndrome patients with pulmonary involvements. Clin Exp Immunol. 2005 March; 139(3): 558–568.
[174]Yee SB, Ganey PE, Roth RA. The role of Kupffer cells and TNF-alpha in monocrotaline and bacterial lipopolysaccharide-induced liver injury. Toxicol Sci. 2003 Jan; 71(1):124-32.
[175]Yi AK, Tuetken R, Redford T, Waldschmidt M, Kirsch J, Krieg AM. CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species. J Immunol. 1998 May 15; 160(10):4755-61.
[176]Yung RL, Richardson BC. Role of T cell DNA methylation in lupus syndromes. Lupus 1994; 3:487–91.
[177]Zandman-Goddard G, Shoenfeld Y. SLE and infections. Clin Rev Allergy Immunol, 2003, 25(1):29-40.
[178]Zeuner RA, Verthelyi D, Gursel M, Ishii KJ, Klinman DM. Influence of stimulatory and suppressive DNA motifs on host susceptibility to inflammatory arthritis. Arthritis Rheum. 2003 Jun; 48(6):1701-7.
[179]Zhu FG, Reich CF, Pisetsky DS. Inhibition of murine macrophage nitric oxide production by synthetic oligonucleotides. J Leukoc Biol. 2002 Apr; 71 (4):686-94.
[180]Zhu FG, Reich CF, Pisetsky DS. Inhibition of murine dendritic cell activation by synthetic phosphorothioate oligodeoxynucleotides. J Leukoc Biol. 2002 Dec; 72(6):1154-63.
[181]Zimmermann S, Egeter O, Hausmann S, Lipford GB, Rocken M, Wagner H, Heeg K. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J Immunol. 1998 Apr 15; 160 (8):3627-30.
[182]胡大利.模拟人微卫星DNA的寡核苷酸对人免疫细胞活化的抑制作用[D].吉林:吉林大学白求恩医学院,2008.